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ABSTRACT
In this study, we have explored the application of the Layer-by-Layer (LbL) 
assembly technique for improving injectable drug delivery systems of low soluble 
anticancer drugs (e.g. Camptothecin (CPT), Paclitaxel (PTX) or Doxorubicin (DOX)). 
For this study, a polyelectrolyte shell encapsulates different types of drug nanocores (e.g. 
soft core, nanomicelle or solid lipid nanocores).The low soluble drugs tend to crystallize 
and precipitate in an aqueous medium. This is the reason they cannot be injected and may 
have low concentrations and low circulation time in the blood. Even though these drugs 
when present in the cancer microenvironment have high anti-tumor inhibition, the 
delivery to the tumor site after intravenous administration is a challenge. We have used 
FDA-approved biopolymers for the process and elaborated formation of 60-90 nm 
diameter initial cores, which was stabilized by multilayer LbL shells for controlled 
release and longer circulation. A washless LbL assembly process was applied as an 
essential advancement in nano-assembly technology using low density nanocore (lipids) 
and preventing aggregation. This advancement reduced the number of process steps, 
enhanced drug loading capacity, and prevented the loss of expensive polyelectrolytes.
Finally, we elaborated a general nano-encapsulation process, which allowed these 
three important anticancer drug core-shell nanocapsules with diameters of ca. 100-130 
nm (this small size is a record for LbL encapsulation technique) to be stable in the serum 
and the blood for at least one week, efficient for cancer cell culture studies, injectable to
mice with circulation for 4 hrs, and effective in suppressing tumors. This work is divided 
into three studies. The first study (CHAPTER 4) explores the application of LbL 
assembly for encapsulating a soft core of albumin protein and CPT anticancer drug. In 
order to preserve the activity of drug in the core, a unique technique of pH reversal is 
employed where the first few layers of the LbL shell are assembled at acidic pH 3, and 
the final layers (2-3) are assembled at a slightly basic pH of 7.4. These LbL-encapsulated 
nanocores are not stable and immediately aggregate in water or the serum. A final layer 
of 5 kDa PEG was assembled to improve circulation time. It showed higher colloidal 
stability in PBS, high drug loading concentration of 0.5 mg/mL, and an improved drug 
chemical stability in Fetal Bovine Serum with high lactone fraction of 99%. It also 
showed 3 times improved cytotoxicity against glioblastoma cancer cells. For the first 
time we applied a new method of the LbL capsule assembly at different pH values, the 
first 4 bilayers at pH 3, and the following 3 bilayers at pH 7.4.
In the second study (CHAPTER 5), the developed LbL assembly for low 
solubility drug encapsulation was extended for the delivery of PTX loaded in nanomicelle 
cores. PTX, as a nanomicelle core, is encapsulated with fewer layers of LbL assembly, 
followed by an extra layer of PEG (PEGylation). A significant improvement was seen in 
reducing the process steps through reduction in the number of LbL layers, while smaller 
nano-colloids, -100 nm, were produced with improved drug loading capacity, higher 
cytotoxicity, and high mice survival rate.
In the third study (CHAPTER 6), we have applied the concepts learned and the 
techniques developed from the previous two studies to modify the surface of the 
nanostructured solid lipid carriers (NLC) with LbL architecture, plus extra PEGylation.
V
The NLC are co-loaded with DOX and docosahexaenoic acid (DHA). This study is an 
attempt to further increase drug circulation time in the blood. We improved the colloidal 
stability with a narrow distribution size, 128 nm, polydispersity of 0.098, a higher 
longevity in the blood, a 1.5 times lower accumulation in the liver, a 2.25 times higher 
accumulation in tumors, and a significant ~3.5 times greater tumor growth inhibition in 
4T1 murine tumor model in mice.
In conclusion, we developed a general model of an LbL nanoassembly core-shell 
drug delivery system of three anticancer drugs. The capsules had diameters of ca. 100- 
170 nm, were stable in the serum and the blood for three weeks, were injectable to small 
animals with a circulation time of 1-4 hrs., and effectively suppressed cancerous tumors 
in mice.
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CHAPTER 1
INTRODUCTION
About 40-60% of anticancer drugs developed have low bioavailability due to their 
hydrophobic nature [53]. Even though they are effective when present at the tumor 
microenvironment, the delivery to the site is a challenge. A lot of research is being done 
to improve their delivery for different types of administrations. One of the most common 
mode of chemotherapeutic delivery is through a systemic circulation. Different drug 
formulation techniques are employed for delivery of such low soluble anticancer drug.
1.1 Brief overview of current low soluble drug delivery methods
Drug delivery system that use nano- and micro-carrier systems for parenteral 
administration are currently under extensive study. Initial developments in micro-drops 
[38,39] and miceller nanocarriers [40-42] of hydrophobic drugs or molecules led to a 
new line of research in drug delivery systems. In an article by Guzey et al., an attempt 
has been made to improve emulsions through Layer-by-Layer (LbL) assembly on the o/w 
based emulsion system. They have also mentioned the multilayer emulsions, which have 
better stability to different ambient conditions [39]. Similarly, hydrophobically modified 
saccharides, such as starch, was encapsulated in oil/water (o/w) emulsion of triglyceride 
oil Miglyol 812F as an oil phase and buffer solution as a water phase. Better
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emulsification was observed under turbulent flow and other kinetic factors, eg. kinematic 
viscosity [38].
A step forward was taken where micro-drop emulsion based, micro-micelles were 
formulated in nano-scales. In Torchilin et al., they described the formulation of 
polymeric micelles, which was formulated by using amphiphile copolymers [52]. It also 
mentions a special category of micelles formed by conjugation of hydrophilic polymers 
with lipids, thus forming lipid core micelles. An example is Poly-Ethylene-Glycol as 
copolymer with Phosphatidyl-ethanolamine (PEG-PE). It was found to have an enhanced 
permeability and retention (EPR) effect. The polymeric micelles had a more effective 
bio-distribution in mice by improving the solubility of low soluble drugs [41, 52]. It was 
observed that it was easy to control the size and loading capacity based on composition of 
water soluble polymers and the lipid. In another instance, PEG was copolymerized with 
polyelectrolyte, PEG with polycation, Poly-L-lysine (PLL) and polyanion, Poly(L- 
glutamic acid) (PGA) with PEG [40]. The major limitation of micro-drops and micellar 
nanocarriers was that they had a low loading capacity [58].
Another approach was to have micro-capsules with sacrificial cores. They are 
called microcapsule shells. The shell is composed of multilayers of polyelectrolytes. In an 
article by Koker et al., calcium carbonate (CaCCb) was used as a sacrificial template in 
the core and further coated by biodegradable polyelectrolyte LbL layers i.e. 2 to 4 
bilayers of alternating Dextran sulfate (DS) and poly-L-arginine. The CaCOs was 
dissolved in resuspending microparticles in EDTA buffer solution at pH 5.4 [43]. They 
concluded that biodegradable polyelectrolytes based micro shells were less toxic, as 
tested in vitro. Here, based on the number of bilayers, the stability of the microcapsules
after intracellular uptake was determined. Another way to form hollow shells from LbL 
assembly was by lyophilizing out frozen cyclohexane in the core. LbL assembly of 
polyelectrolytes were done on top of it, at a temperature just below the freezing point of 
cyclohexane [51]. Although the hollow shell technique is quite novel, irregular release 
due to non-uniform destruction of hollow core and low drug loading capacity were its 
limitations.
A novel method of conjugating the drug with the polymer itself has been currently 
a major research of study for effective drug delivery. Since most of the anticancer drugs 
used for chemotherapy have a low half-life of systemic circulation and untargeted 
delivery, this leads to adverse side effects [45]. PEG conjugated with drugs was one of 
the first and most successful drug delivery systems, but its low biodegradability leads to 
toxicity. It also showed a low drug loading capacity. An effective PEG conjugate with a 
CPT derivative, SN-38 was formed as EZN-2208 (drug loading of 3.7%) [52].
Biopolymer based drug carrier for low soluble drugs is becoming quite common 
and is commercially available in the market. The most common of them are polyesters 
and polyamino acids, such as poly (L-glutamate) and poly (L-aspartic acid) [58]. The best 
example of commercially available biopolymeric drug carrier is Abraxane, in which 
albumin, as a biopolymer, is a carrier of PTX. The nano-encapsulations are 
biocompatible. LbL assembly with biopolymer based polyelectrolytes is one of the good 
methods to encapsulate drugs [49].
1.2 Research Goals
The objective of this research will be to make the low soluble drugs, e.g. CPT, 
PTX, and DOX deliverable in higher concentrations to the site of the tumor. To 
accomplish this objective, the formulations from these drugs are made hydrophilic in 
nature by encapsulating it with amphiphiles and polyelectrolytes. The increased solubility 
will increase the circulation time in the blood.
In this work, we developed the Layer-by-Layer (LbL) polyelectrolyte 
encapsulation method (initially at the Max Planck Institute, in Germany by H. Mohwald, 
G. Sukhorukov, F. Caruso, E. Donath, and others). Our development allows for a 
twenty-fold decrease of LbL capsule size, from typically 5 micrometers in the original 
German works to 100-170 nm in our approach [54-57]. A new improvement in LbL 
technique is tried on the nano-encapsulation of low soluble anticancer drugs. We made 
two innovations in this work: 1) Nanocore drug formulation through coacervation of drug 
with amphiphile including lipids; 2) Instead of repeated washing after each layer 
deposition, a washless technique was used for polyelectrolyte LbL assembly. This 
increased the drug loading capacity by 60 wt. % and made the process simpler. The 
following aims will be performed to test the above hypotheses 1,2:
1) To optimize the size of nanocapsules to a small size of 100-170 nm: Titrated amounts 
of surfactants and polyelectrolytes needed per weight of drug will help in obtaining the 
low hydrodynamic size of the nanocapsules. It is known that particle sizes less than 
200 nm easily pass the EPR at the vesicles by the tumor cells. This size is critical in 
order to attain longer circulation due to prevention of uptake by the liver [127].
2) Washless LbL assembly under continuous sonication with capsule PEGylation: We 
developed nano-colloids stabilized with coating of biocompatible surfactants and 
polyelectrolytes. First of all, the drug nano-cores developed were often lighter than 
water. Secondly, the washless technique reduced the steps in formulation processing, 
thus reducing waste of expensive polyelectrolytes and also the drug. Examples of such 
substances are Bovine Serum Albumin (BSA), poly amino acids, poly saccharides and 
commonly used surfactants for biological activities (e.g. poly vinyl pyrrolidone, 
polysorbate). Further Poly Ethylene Glycol (PEG) tails were attached to the outermost 
surface of nanoparticles for further colloidal stability, thus increasing the circulation 
time.
3) To restore the chemical structure and activity of the encapsulated drug: CPT is present 
in its active form, lactone, and inactive form, carboxyl. LbL assembly will act as the 
diffusion barrier for exterior medium to degrade the drug. QCM can be used to study 
the effect of LbL assembly. The main objective of the formulation is to make the drug 
soluble and to restore its active form for efficient systemic circulation until it finally 
reaches its targeted site o f action.
4) To optimize the nano assembly according to the required drug release rate: It is 
important to tune the release rate of drug from the nanocapsules to match the required 
dosage. The final targeted model of the nanocapsules should release sustained amounts 
of drug when it reached the targeted site, i.e. the tumor cells.
5) Testing LbL nano-formulation on cancer infected mice through intravenous injections 
(in collaboration with Northeastern University, Dept, of Pharmaceutical Sciences).
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1.3 Dissertation Overview
The dissertation is divided into introduction, literature review, instrumentation, 
and three chapters of further results. The second chapter reviews the poorly water soluble 
anticancer drug formulations, their limitations for delivery, the basics of LbL assembly, 
specificity of its architectural encapsulation, the different techniques developed for past 
LbL based drug delivery systems, the industrial sonication method for nano-colloid 
formulations, and the washless LbL technique used to formulate different drug cores.
The third chapter briefs about the instruments used for various analytical 
characterization, such as UV-Vis spectroscopy, Fluorescent Spectroscopy, HPLC, FT-IR, 
TGA; for surface characterization, such as Contact angle and Quartz Crystal 
Microbalance (QMC), and for morphological characterization, such as cryo/TEM, SEM 
and optical microscope.
The fourth chapter describes the LbL coating based nanocapsular formulation, 
with CPT and BSA in the core, particle size ~200 nm. The biocompatible poly amino 
acid based polyelectrolytes used for LbL assembly are mentioned. During the 
formulation, the unique pH reversal step included is mentioned. It was employed to 
preserve the active form of CPT, lactone. The morphological characterizations were 
through the particle size analyzer, SEM, TEM; the drug chemical characterization by 
UV-Vis spectroscopy; the LbL architecture by zeta potential and QCM studies, and 
finally the in vitro release studies and the cell viability studies in brain glioblastoma cell 
culture were discussed.
The fifth chapter is about development of nano-micelle based PTX core, with non 
ionic surfactant, a cremophor, such as Tocopherol polyethylene glycol succinate (TPGS)
and an ionic surfactant, with further encapsulation by LbL films using the washless 
technique, its circulation optimization by labelling with PEG tails, and finally testing its 
anti-tumor activity in mice. A stable dispersion of -100 nm was formulated with a high 
loading capacity of -40%.
The sixth chapter is the application of LbL advanced technique as described in 
Chapters 4 and 5 for enhancement of circulation of soft lipid cores with DOX 
hydrochloride in the mice. An enhancement in antitumor activity is demonstrated by 
injecting the improved drug formulation in the tumor infected mice.
The seventh chapter concludes by pointing out the achievements made in the 
previous Chapters, 4, 5, and 6. It also gives an outline for the future work that has to be 
done in order to progress in such a research direction.
CHAPTER 2
BACKGROUND AND THEORY
This chapter is a brief introduction to water insoluble anti-cancer drugs which 
have not been commercially available or popular in the market. Their low solubility in 
the blood is the reason for short systemic circulation and negligible bioavailability. 
Furthermore, we will introduce a well-known nano thin film deposition process of the 
LbL assembly technique. We will discuss its specificity on nano sized core preparation. 
Then we will move forward to its application in drug delivery system development. We 
will discuss the industrial sonication process used in assistance with nanoparticle core 
preparation followed by LbL assembly. Here, during the LbL assembly process, after 
each polyelectrolyte (PE) film deposition step, a washing step follows to remove excess 
and free floating polyelectrolytes (PEs). Finally, we will give a background of the 
washless LbL approach, which comes into play for colloidally stable nanoparticle 
formulation. We will conclude by discussing the non-washing approach we will be using 
to formulate in this research dissertation:
1) Soft protein / CPT cores
2) Solid Lipid Nanocarriers (SLN) LbL formulation
3) Emulsion core or miceller core
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2.1 Cancer and Low Soluble Anti-Cancer Drugs
More than 40% of pharmacologically active compounds exhibit poor solubility in 
water [34]. According to Biopharmaceutic Drug Classification, they come under Class 4 
[65]. They are compounds which are have both low solubility and poor intestinal wall 
permeability [34]. A current emphasis of drug delivery system (DDS) research is in the 
development of injectable nanoparticle formulations that allow the slow release of the 
encapsulated drug in the bloodstream [26,27]. A number of drugs, such as Curcumin, 
Tamoxifen, Lapatinib, PTX, and CPT, have been approved by Food and Drug 
Administration (FDA) but do not have a formulation for delivery at sufficient 
concentrations. Numerous drugs have been synthesized for chemotherapy, but some of 
these drugs are water insoluble/hydrophobic (Figure 2-1) and are difficult to administer 
through the systemic circulation (i.e. Intravenous (IV) pathway).
(a)
HO O(c) (d)
Figure 2-1: Chemical formulas of some poorly soluble anticancer drugs (a) Curcumin, 
(b) PTX, (c) Tamoxifen, and (d) CPT.
10
The respective solubility limit of these drugs in water are: Curcumin <0.1 
mg/mL, Tamoxifen 0.1 mg/mL, and for PTX and CPT < 0.001 mg/mL. Later in this 
chapter, we will discuss the different approaches we will take to improve the parenteral 
delivery of CPT, PTX and DOX as an injectable formulation. Based on the chemical 
stability at physiological pH and the solubility, we will use different types of nano-core 
carrier followed by LbL coating on top of them for better functionalization, colloidal 
stability, and improved circulation.
2.2 Basic Concept of Layer-by-Layer Assembly Technique
Layer-by-Layer assembly is a well-known and a common industrial approach. A 
short historical overview of stable coatings formation on particles of different shape and 
size (from microparticles to sacrificial microcores for empty microcapsules sensitive to 
pH and then down to shells of variable architecture formed on nanoparticles to alter their 
surface properties) is discussed in this section [22]. The weak and the strong PE form 
different film uniformity. The film growth with number of alternating polycation and 
polyanion deposition is either linear or exponential. This characteristic is dependent on 
the ionic strength of PEs being deposited. In Buron et al. this phenomenon was shown on 
a flat surface. It was demonstrated that with an increase in ionic concentrations, the 
polymer adsorption was decreased. The effect of bivalent ions, Ba2+ and Zn2+ was higher 
as compared to that by monovalent ion, Na+ [23].
A unique approach was to deposit gold nanoparticles coated with LbL films, then 
slowly dissolving the inner gold with cyanide ion, thus creating a hollow nanosphere 
[28]. It was shown that higher number of layers, i.e. at least 20 layers (PAH/PSS) leading 
to 7.5 nm thick coating, was possible. It is a good example of sacrificial nanocores. It was
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observed that if excess PSS destabilizes the colloidal stability of the dispersion, then it 
was necessary to remove the excess PE before the next layer of PE is being deposited. 
Another example for sacrificial core after LbL assembly of PEs is discussed in Boudou et 
al. [36]. Later, we will discuss the washing process of the LbL coating technique.
2 3  Specificity of LbL Assembly on Nanosized Cores
Limitations of length of polyelectrolytes and nature of the chain suitable for LbL 
coating on nanosized objects due to competition of the processes of nanocores 
aggregation and wrapping around a single particle was discussed [20, 39]. In practice, the 
low molecular weight polyelectrolytes must be <65 kDa because space for the polymer 
chain absorption onto the nanosphere-like structure is limited [20]. However, 
polyelectrolytes of high molecular weight are rarely used because their high molecular 
weight results in a thicker coating and rapid aggregation. Due to high charge density 
around the polyelectrolyte chain, it makes the chain more rigid to bend and it tends to 
adsorb flat on the surface. It has less effect on the thickness of the film. See Figure 2-2.
(a) Low Ionic Strength (b) High Ionic Strength
(high charge density / more rigid) (low charge density / more flexible)
Figure 2-2: Polymer orientation on a surface based on its nature i.e. ionic strength: (a) 
Low ionic strength, (b) High ionic strength [20].
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The pH and ionic strength strongly influence polyelectrolyte interaction and 
nanoparticle aggregation. The pi value determines the pH at which the net ionization of a 
molecule is zero. A careful selection of pH, especially for LbL assembly, is important to 
confirm that the charge on particle surface and the adsorbing polyelectrolytes are 
sufficiently high [20]. In an article by Buron et al., it is shown that the concentration of 
polyelectrolyte and the type of salt has an influence in the colloidal stability of 
dispersion. The study of film deposition was done by reflectometric signal during the 
process, and after drying under ellipsometry [23].
Polyelectrolyte shell stability in isotonic salt solutions and in vivo calculation 
studies will be discussed [23,31, 39]. It was observed that with an increase in salt 
concentration, the polyelectrolytes film thickness increased exponentially to certain 
concentration, i.e. 0.01 M. After that at 0.1 M concentration, the curve became linear 
(Figure 2-3a). It was also observed that the bivalent salt ions such as Zn2+ and Ba2+ gave 
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(a) (b) (c)
Figure 2-3: (a) Effect of different concentrations of monovalent NaCl and (b) Effect of 
divalent salts on quantity of polymeric absorption through reflectometric signal, (c) 
Comparison of reflectometry and ellipsometry measurements for film thickness with 
respect to number of deposited layers [23].
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Chodanowski et al. used a simulation study to understand the trends in 
conformation of polyelectrolyte absorption on a charged particle: 1) based on the ionic 
concentration in the dispersion medium and 2) the particle size. They used a Monte Carlo 
simulation, and the electrostatic interactions were in the Debye Huckel assumptions [31]. 
Figure 2-4 shows that net charge, |Q*|, increased linearly with particle charge, Q. An 
increase in the concentration of salts led to a screening effect against the particle surface 
charge, thus making polyelectrolyte absorption easier with an increased charge reversal. 
An exception was observed for an increase in particle / size ratio, op / om > 6 and N = 
100, where the analytical data did not match the theoretical model. They suggest that this 
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Figure 2-4: Variation of Net charge |Q*| with respect to: particle charge as Q, particle/ 
monomer size ratios as ap/ am and ionic concentration as Ci [31].
The polyelectrolyte concentration in LbL shell formation [39] is a critical factor to 
have a complete saturation of the surface. The minimum amount of PE required to coat 
the surface completely at a nanoscale level is simultaneously influenced by the molecular 
influence of the PE to the chain length, conformation at different pH or charge density,
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and flexibility of the polymer chain [76]. An interesting theoretical model for estimating 
critical PE concentration needed for complete surface saturation was discussed in 
Mc.Clements et al. [77]. It assumes that the PE concentration added to the dispersion 
system is completely adsorbed on all of the particle surfaces. If the polyelectrolyte 
concentration is less than the saturation concentration (Csat) or the emulsion/droplet 
collision concentration ( C a * )  i.e. 0  < C < (C sat or Ca<1s), then
where <}> is the volume fraction of particles, T s a t  is the surface load of PE at saturation 
concentration (in kg m"2), r is the radius of spherical nanoparticles (in m), rPE- is the 
effective radius of PE polymeric molecules in the solution (in m).
Free polyelectrolytes which are not adsorbed to the spherical nanoparticles and 
are floating freely in the dispersion medium causes depletion attraction (Figure 2-5a). If 
the PE concentration is less than the depletion concentration, Cdep, then a multilayer PE 
film formation is possible. If it exceeds Cdep, depletion flocculation occurs. It was also 
observed that a stable multilayer colloidal dispersion is less possible for very low particle 
radii (r < 0.15 pm). See Figure 2-5 b.
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Figure 2-5: (a) Schematic shows events that happen when concentration of charged 
polyelectrolyte is increased in a colloidal dispersion medium, having oppositely charged 
particles; (b) Influence of droplet or emulsion size on critical polyelectrolyte 
concenration [77].
Excipients or high concentrations of solubilizers are generally used for the micro/ 
nanoparticle formulations. They are non-ionic polymeric excipients, which cannot be 
removed from the mixture without compromising colloidal stability of dispersion. For 
LbL assembly on nanocores, the amount of PE required in the presence of excipients (e.g. 
polyvinylpyrrolidone, polyethylene glycol, sucrose, glycerol) is many fold more than the 
PE required without excipients [10-12, 78, 79]. For example, 3-10 layers of 
bio/polyelectrolytes (chondroitin sulfate, Poly L-Glutamic acid (PGA), Poly Aspartic 
Acid (PAspA), Poly-L-Lysine (PLL), Poly Lactic-co-Glycolic Acid (PLGA), Dextran 
Sulfate (DS), carboxymethyl cellulose, and Protamine Sulfate (PS)) were successfully 
deposited on Au-modified quartz flat supports and on PROMAXX® insulin microcores 
of a 1 pm diameter in aqueous solutions composed of 16% polyethylene glycol MW 
3350 Da and NaCl [79].
Shells of different architecture consisting of heparin, BSA, and Poly-L-lysine- 
Block-copolymer-PEG (PLB) layers were assembled on the surface of PTX and CPT
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nanocrystals in aqueous solutions containing Poly Vinyl Pyrrolidone (PVP) using the 
non-washing LbL assembly technique [11,12, 78]. The details of this technique will be 
discussed further in Section 2.6. PVP is a non-ionic surfactant, which is extensively used 
in pharmaceutical formulations, and is applied at the core preparation stage to enhance 
stability of formed drug nanocrystals. PVP does not change the amount of polyelectrolyte 
required for layer formation by complete ^-potential charge reversal [12].
2.4 LbL Assembly Techniques for Drug Delivery Applications
This section will describe various techniques other than the sonication method, 
which was used in assistance with LbL assembly for encapsulations of micronized drugs 
and contrasting agents. In a review article by Ariga et al., a functional hollow shell was 
formed out of sacrificial core of MnCC>3, further coated with DNA-Spermidine 
complexes. After the core was dissolved, the shell with DNA-Spermidine was left. A 
further decomposition leads to release of Spermidine, thus entrapping DNA completely 
[2]. Similarly, SiC>2 core structures, coated with LbL layers were used for oligopeptide 
antigens. In this review, an article by Fukui et al. has shown a novel method of 
combining liposomes and LbL assembly to form hollow shell structures.
Responsive materials for triggering some release in a drug delivery system play 
an important role. An innovative idea to apply LbL technique for the assembly of 
responsive polymers on a nano/micro drug carrier was utilized [3]. There can be different 
ways to crumble this film at a particular response such as dissolution of the cross-linker 
between LbL films based on pKa of assembly or higher ionic concentration in the 
medium. These techniques can be used reversibly in order to make the LbL assembly 
more permeable for drug loading into the capsule, or irreversible for LbL film
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disintegration. Here, Erel-Unal et al. showed that the LbL film could be destabilized with 
varying H-bonded bilayers having stability at different pH [59]. Poly (N-vinyl 
caprolactam)/poly (L-aspartic acid) combination degraded at pH ~3, while a Poly(N- 
vinyl caprolactam)/Tannic acid combination degraded at pH ~10. In Wohl el al., work 
with Redox responsive films has also been described. Here, Prussian blue has been used 
which becomes colorless by electrochemical reduction (Fe3+ to Fe2+). In another instance, 
oppositely charged forms of poly (Ferrocenyl silane) were used as LbL templates [3]. 
These are examples of methods for inhibiting interlayer interactions, leading to LbL film 
disruption. Another category of responsive LbL film is by degradation of the film 
components, either by mechanical or heat destruction. The swelling of encapsulated 
material leads to disruption of LbL film. For instance, a hydrogel is loaded with drug and 
then LbL is swapped. The swelling rate is controlled by the crosslinking density of the 
hydrogel (See Figure 2-6).
- - - - -
(a) (b)
Figure 2-6: (a) Dextran hydrogel encapsulated with LbL assembly. Swelling of hydrogel 
leads to osmotic pressure and rupture of LbL film [3]; (b) Phase transition of PVPON-b- 
PNIPAM micelles due to temperature change and poly(methacrylic acid) reversibility on 
cooling from 37° C to 20° C [61].
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Metal nano-cores absorb laser light and convert it into heat. LbL assembly on 
metal cores, silver, gold or TiC>2, is destroyed by layer targeting. This concept has been 
used in research for cell related targeting and its destruction [60]. Thermo-responsive 
polymers incorporated in the LbL films are another innovative way of drug 
encapsulation. Poly (N-isopropylacrylamide) below its lower critical solution temperature 
is hydrophilic in nature and is hydrophobic above it [61].
The above mentioned methods of drug delivery are based on encapsulation of 
drug in the core, followed by LbL assembly. A new concept of incorporating secondary 
drug/bioactive agent (growth promoting hormone e.g. cytokines) between the LbL 
assembly architecture was mentioned in multiple articles by Haidar et al. [62-64]. Here, 
bone morphogenetic protein (rhBMP-7) is entrapped between the LbL shells of alginate 
(AL) and chitosan (CH) assembled around a drug loaded with liposome in the core.
The formulation was nano-scalable and nontoxic with a controlled release of 
rhBMP-7. According to the number of bilayers, the release profile was tunable, with 
higher bilayers leading to a slower release. A schematic of the architecture is shown in 
Figure 2-7a, and a sustained release profile for 45 days is shown in Figure 2-7b.
Spray assisted LbL functionalization of printed nanoparticles is another novel 
technique in nanomedicine. This method of printing nanoparticles was developed to 
overcome the limitation of repeatability and scalability of nano-drug delivery systems. 
The surface molecular properties of nanoparticles are important for the desired biological 
effects. LbL being the most simple and effective way to coat surfaces was employed to 
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Figure 2-7: (a) Drug or bioactive agent, rhBMP-7 in the LbL shell of Alginate (AL) and 
Chitosan (CH) around Liposome (L) [32]; (b) An in vitro cumulative % release. This 
graph is reconstructed from the original article [32,64].
Most drugs today are poorly water soluble, i.e. ~ 40% [34], and therefore cannot 
be administered orally or systemically. Especially for intravenous administration, a 
promising approach is to coat such drugs with LbL assembly. The PE coating acts as a 
barrier between the drug and the outside aqueous environment. Several methods can be 
used to encapsulate drugs before they are coated with LbL assembly: emulsion based 
core prepared by standard emulsification techniques, coating drug micro- /meso-crystals. 
The general process for emulsion carrier-coated LbL formulation is to form an emulsion 
core with a lipid soluble drug by various methods of emulsification, e.g. homogenization. 
The core is then coated with LbL assembly. The emulsion will have amphiphile/s along 
with the drug (Figure 2-8), having a net surface charge, based on which the +/ - charged 
polyelectrolyte is chosen for assembly [66]. Leporatti et al. note that the drying of such 
micro/nano capsules leads to their collapse [67]. LbL assembly of liposomal core (50-200 
nm) with other counter polyelectrolytes around a sacrificial micro-core, e.g. of silica, was 
termed as capsosomes [34],
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(a) (b)
Figure 2-8: (a) Schematic of emulsion encapsulation by LbL assembly; (b) The top are 
the SEM images of 3 and 4 layers of PE (scale bar being 10 pm), while the bottom shows 
SEM images of dry encapsulations (scale bar being 20 pm and 2 pm for left and right 
images respectively) [66].
Formation of such emulsion systems under continuous sonication is called 
sonication-assisted emulsification. High-intensity ultra-sonication (20 kHz) forms 
microspheres that are stable for months [34]. The stability of such microspheres in blood 
circulation can be increased by beautifying the surface with LbL architecture. 
Polyelectrolyte assembly on the surface is under continuous sonication to generate a 
uniform assembly. The principle of cavitation is explained in the next section on 
industrial sonication-assisted NP core formulation. A good application of this technique 
was a combination of magnetic nanoparticles with protein containers as a targeted 
delivery [68]. LbL assembly directly on the crystals of poorly soluble drug leads to 
increased encapsulation capacity of the formulation. The sonication-assisted 
encapsulation of ibuprofen micro-crystals with chitosan as positive polyelectrolyte, 
dextran sulfate, carboxymethyl cellulose and sodium alginate as negative polyelectrolyte 
leads to electrostatically stable microcapsules [51].
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The LbL approach provides greater versatility for encapsulation of low soluble 
drugs and also to functionalize the surface. The technique is easy and solves many issues 
of stabilization of nanocapsules. A delivery system can be easily made more 
biocompatible by incorporating amino acid-based or polysaccharide-based natural PE. 
The major drawback of the technique is that it is tedious [35]. In industries, process steps 
are reduced by assembling multiple layers one after another without intermediate 
measurements or wait time.
2.5 Industrial Sonication-Assisted NP Core Formulations- LbL Techniques
Top-down disintegration of poorly soluble drug crystals to its micro-/meso- 
crystalline form is being employed to produce an effective nano-formulation with 
reduced production cost. While nano-emulsions and polymeric micelles are kind of a 
bottom-up approach, these formulations are further stabilized and functionalized by LbL 
assembly under ultrasonication.
Nano-crystallization is an initial concept based on the Noyes-Whitney equation, 
which mathematically proves that particle size reduction increases the surface area, which 
in turn increases the dissolution rate [5]. The equation is
Eq. 2-3
where D  is the Diffusion coefficient, h is the thickness of the diffusion layer, V is the 
volume of the dissolution medium, Cs is the saturation solubility, and C is the 
instantaneous concentration.
Various Top-bottom approaches can be used to form nano-crystals: Nano­
precipitation, high pressure homogenization, wet/dry ball milling, and ultrasonication. In
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all of these cases, the application of ultra-sonication cavitation technology has been 
increased over the last decades. Ultra sonication cavitation of bubbles involves the 
expansion and collapsing of bubbles in the liquid, thus creating high pressure and 
temperature. These effects crush particles to smaller pieces [70, 75].
Nanoprecipitation involves restrictive growth of low soluble drug crystals. Here, 
the drug is dissolved in organic solvent to a supersaturated concentration, forming small 
crystal seeds by nucleation. The transfer of such nanocrystals with nucleation stabilizers 
e.g. poly vinyl pyrrolidone, Tween 80, or lecithin, into aqueous solvent, under 
ultrasonication, leads to nanocrystals with tunable size and stability. In Zheng et al. the 
poorly soluble anticancer drug Curcumin was dissolved in ethanol and nucleated under 
powerful sonication by a continuous addition of an aqueous polyelectrolyte (polycation) 
















Figure 2-9: (a) Zeta Potential LbL assembly on curcumin core, at pH 6.5, with 
alternating PAH and PSS. This graph is reconstructed from the original article, with 
minor imperfections; (b) Release profile of curcumin, with UV absorbance at 480 ran [6].
The rate of addition of the aqueous medium and initial drug concentration 
determined the effective particle size. For 0.4 mL/min addition rate, -320 nm particle
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size and for 0.05 mL/min, ~120 nm size was obtained. See Figure 2-9b for the improved 
release profile as compared to the free curcumin drug.
Another example is nano-encapsulation of PTX drug, under ultrasonication, 
followed by LbL assembly of Protamine Sulfate as positive polyelectrolyte and Albumin 
as negative polyelectrolyte [7,10]. The process was done in PBS, pH 7.2. The rate of the 
drug release can be tuned by changing the number of layers in the LbL assembly. To 
overcome multidrug resistance for ovarian cancer targeting, combination therapeutics of 




Figure 2-10: (a) Schematic of LbL architecture around PTX (PTX) nanocrytal; (b) 
Particle size distribution of PTX LbL formulation; (c) Lapatinib/PTX LbL nanocolloids 
cytotoxicity assay against P-gp overexpressed ovarian cancer cells (P < 0.05*, P <
0.01**, P < 0.0 01***); where PTX- PTX, CTR - Control [8].
High power ultrasonication was utilized to break the drug crystals into small 
particles. It led to a great improvement in colloidal stability with effective particle size of 
100-200 nm, a high drug loading capacity of 70% w/w, with a sustained controlled 
release and an outer negative charge. It also showed an improved cytotoxicity against 
overexpressed glycoprotein, P-gp (multi drug resistant protein, MDR-1) in ovarian cancer
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cells OVCAR-3 [8]. Figure 2-10c shows the MTT assay results. Similarly, sonication has 
been used to prepare liposomes, nano-colloids formed out of emulsions, or soft cores [9].
High pressure homogenization and media milling are the top-down disintegration 
processes. High pressure homogenization is commonly used in the pharmaceutical 
industry to prepare nano-crystalline drug [5]. For this method, drug and stabilizers are 
mixed and passed through a narrow gap at a high pressure of 500-2000 bar. This pressure 
creates an intensity of cavitation similar to that obtained in ultrasonication, with high 
collision and shearing effects. The size of the nanocrystals can be manipulated based on 
the number of cycles run and on the pressure and temperature of the process in the 
homogenizer. An example of this method is commercially available through oral tablets, 
Triglide® (Fenofibrate), an antihypercholesterolemia. The oldest method of nanocrystals 
formulation is through media milling, which is done by milling pearls in the presence of 
the drug, water, and stabilizers [5]. It is cost-effective, and some of the commercially 
available drugs are Estrasorb ® (Estradiol), and Restasis (Cyclosporine). The limitation is 
for temperature sensitive drugs, as the milling process generates heat. Also, a significant 
amount of the drug is lost during the process because it adheres to the inner surface of the 
milling chamber.
The top-bottom approach contrasts with the bottom-up approach, which is 
becoming common in the industries. Sonication-assisted methods of nanoemulsions and 
polymeric micelles are the major techniques of practice. Use of LbL assembly is also a 
bottom-up approach. In general, LbL assembly is a tedious process, with a washing step 
to be performed after each layer adsorption. The purpose of washing is to remove the 
unbound polyelectrolytes from the dispersion mixture. A novel, less tedious method of
the washless LbL technique has now been under academic investigation. Its application 
to further stabilize nanoprecipitation, nanoemulsion, and polymeric micelle-based low 
soluble drug cores is discussed further in Section 2.6. Lvov et al. has discussed 
sonication-assisted LbL assembly to convert low solubility materials to materials that are 
more aqueous and stable [10]. Sonication assisted disintegration of a drug is a top-down 
approach, while further architectural assembly of polyelectrolytes or other polymers is a 
bottom-up approach. Sonication causes a bubble nucleation effect [73] and has been used 
in combination with LbL assembly (SLbL), for stabilization of nanocolloids with poorly 
soluble compounds (Table 2-1) [10]. Layer-by-Layer assembly technique is a bottom-up 
nanofabrication technique. It is versatile, easy and efficient. In Ariga et a l, applications 
of LbL as a bottom-up approach has been discussed [46]. QCM is a common technique 
for the measurement of LbL assembly on any flat surface. The details of QCM will be 
mentioned in the next sub-section 2.7 [69].
Table 2-1: Experimental results for ultrasonication assisted top-down LbL assembly 









PTX 15 ± 5 PAH, chitosan, PLL
PSS, alginic 
acid, heparin 211 ±40
Tamoxifen 12 ± 7 PAH, PEI PSS, PAA 220 ± 32
Curcumin 18 ± 5 PAH, PS PSS, BSA 107 ± 17
Resveratrol 180 ±40 Chitosan alginic acid 200 ± 30
pigment Orange 13 19 ± 6 PAH, PS PSS, BSA 264 ± 23
2,4-dinitrophenylhydrazine 82 ±20 PAH, PEI PSS 216 ±29
2-mercaptobenzothiazole 27 ±8 PAH, PS PSS, BSA 290 ± 33
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2.6 Non-Washing LbL Technique
The washing step after each polyelectrolyte layer deposition is done to remove the 
excess amounts before the addition of counter polyelectrolyte [19]. A modified version, 
washless LbL assembly, was developed to prevent loss of expensive polyelectrolytes. For 
this technique, a titrated amount of poly electrolyte is added with simultaneous surface 
charge measurement by zeta potential machine. Until a certain desirable zeta potential 
value is reached, the polyelectrolyte is added, then similarly titration of the counter 
polyelectrolyte is measured. This way, the exact amount of PE layer for particular zeta 
potential range is estimated. In Bantchev et al. (2009), this assumption was applied for 
coating titanium dioxide (Ti0 2 > microcores and microfibers.
When the needed PE amount is known, the amount of the produced colloidal 
particle can be readily scaled up. It was explored from the study that various effects on 
the trend of assembly: 1) Based on the amount of particles to be coated, the amount of 
polyelectrolytes increases per layer for an increase in initial particle concentration; 2) 
Based on the length or molecular weight of the polyelectrolyte molecule, a smaller length 
led to less aggregation of particles; 3) The concept behind non-washing LbL assembly 
will be described [19] with an emphasis on the LbL procedure for extra-small and soft 
cores (See Figure 2-11).
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Figure 2-11: (a) Zeta potential values along the titration with PE/layer on 2.5 mg/mL of 
microfiber; (b) Variation in effective particle diameter along the LbL assembly for 
different concentrations of Ti02 particle [19].
The role of PEGylated polyelectrolytes in preserving stability of the nanoparticles 
in non-washing LbL assembly in the presence of salts will be discussed. The application 
of non-washing LbL assembly to different drug cores, discussed in this dissertation are 
for: 1) semi-stable crystalline drug core (PTX) [5, 11,36, 37], 2) soft protein/CPT cores 
[11,12], 3) Solid Lipid Nanocarriers (SLN) LbL formulation [13, 24, 83], and 4) 
Emulsion core or miceller core [15].
Semi-stable crystalline drug cores have been one of the initial methods in 
encapsulating drugs by LbL assembly. It involves core formation by nanoprecipitation of 
semi/crystalline drug nanoparticles using nucleation. Here, the drug is first dissolved in 
an organic solvent, in which it is most soluble. Then, adding it in a supersaturated 
concentration to an aqueous medium leads to drug seed formation by nucleation.
Addition of the stabilizer inhibits checks on excessive crystal growth or agglomeration. A 
further stabilization with LbL assembly with charged polymers is becoming a common 
trend. The choice of solvent and ratio of drug to stabilizer controls the size of the core 
and also its stability.
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In Shutava et al. (2013), an excellent demonstration of this technique has been 
mentioned for formulating a stable drug encapsulation of poorly soluble anticancer drugs 
PTX and CPT, separately. A PTX core was formed by a nucleation method, and the 
crystal growth was restricted by 2.9 mg/mL of polyvinylpyrrolidone, 1.2 mg/mL of 
dioctyl sodium sulfosuccinate (AOT) and 0.36 mg/mL of polysorbate 80 under 
continuous sonication. The process was conducted at 10° C. Further bilayers of 
alternating heparin sulfate sodium (HEP), as anionic polyelectrolyte, and poly-L- 
lysinel6kDa-b-copolyer-methoxy-PEG5kDa (PLB16-5), as cationic polyelectrolyte, were 
assembled on it (Figure 2-12) [11]. While CPT, another low soluble anticancer drug, was 
formed similarly, the core was formed as a soft core with albumin protein. The details of 









Figure 2-12: (a) TEM image of nano-PTX coating with PLB16-5/HEP)3/PLG65 5 shell. 
Visualization was improved by negative staining with ammonium molybdate 
[(NH4)2Mo207], (b) Release profile in water with 2% w/v Polysorbate 80 at 37° C: of 
300 nm PTX nanocolloids prepared by top-down sonication assisted LbL method and 
coated with (PLL/Hep)n shell, where n is number of bilayers; n: 1- 0.5,2-4, 3-8,4-12. 
[11].
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The role of PEGylated surfaces have been studied to provide better colloidal 
stability. A careful examination of the stoichiometry-related colloidal stability was given 
by Schneider and Decher [118]. In the conventional LbL assembly with non-PEGylated 
polyelectrolytes highly concentrated solutions of each polyelectrolyte are needed to 
recharge added particles instantly and, therefore, minimize the time of the existence of 
low or zero charged species [118,119].
2.7 Core-LbL Shell Drug Nanocapsules
Nanocarriers that release the encased drugs in a prolonged or stimuli-responsive 
manner and target specific cells or tissue in human body are under intensive 
investigation. In the field of drug delivery applications, LbL-coated nanocapsules 
combine drug-loaded core matrix and a shell of variable architecture that can consist of 
polyelectrolytes, proteins, nanoparticles, and selected molecules of low molecular weight; 
each part of the composite bears a set of specific functions [41, 119].
200-250 nm nanocrystals of poorly soluble drugs (PTX, Tamoxifen, Curcumin, 
Resveratrol) prepared by top-down disintegration or nanoprecipitation technique were 
coated with two-layer shells of PAH 70 kDa or polyethyleneimine (PEI) of 60 kDa 
followed by PSS 70 kDa. For in vitro release studies, bio/polyelectrolytes (alginic acid, 
chitosan, heparin (Hep), PLL) and proteins (protamine sulfate, BSA) were used for the 
LbL process [6,7,120-122].
Emulsions stabilized by interfacial membranes consisted of sodium dodecyl 
sulfate/chitosan/pectin, p-lactoglobulin/carrageenan/pectin, lecithin/chitosan/pectin with 
an average size in the range of 300-500 nm obtained via electrostatic deposition of one
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polymer after the other without the intermediate washing step show better stability to 
environmental stress under certain circumstances [123, 124].
The protein and cell adhesion resistance properties of LbL films and nanocapsules 
have been of great interest to improve the current drug delivery systems. PEG assembled 
in high density brush-like structures shields the underlying surface from the penetration 
and subsequent adsorption of proteins [125, 126].
As confirmed by QCM-R, electrophoretic measurements, and analytical 
technique, upon adsorption of block-copolymers of PLL and PEG, the surface remains 
accessible for further electrostatic binding of Hep [11, 12, 78]. The thicknesses of a 
PLB/Hep bilayer on flat gold surfaces are comparable for unmodified PLL and PLB 
copolymers. The thickness of 4.5 and 7.5 (PLB16-5/Hep) bilayer films is ca. 5.2 and 7.5 
nm. The surface of PLB/Hep with a PLB outermost layer can be further modified through 
covalent attachment of PEG of 5-20 kDa to the film’s outermost amine groups [12]. The 
mass of mPEG20kDa attached to the film exceeds that of mPEG5kDa by a factor of -1.2 
to 1.7. Although many amine groups remain unreacted on the surface, the further PEG 
attachment is hindered by neighboring PEG tails. Thus, QCM-R is a reliable and accurate 
method to analyze the protein resistance of PEG tails or different LbL polyelectrolyte 
architectural approach.
2.8 Conclusion
Many anticancer drugs are effective in a cancer microenvironment, but are not 
effective when applied systemically because they are poorly soluble in blood. LbL self- 
assembly technique has a lot of applications in the field of film coating on a flat surface. 
The recent applications and better understanding of how it can be employed for the
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encapsulation process at the micro and nanoscale have been studied for some time 
recently. The introduction of sonication assisted improved washless LbL assembly 
technique for nano-encapsulation of drugs have been recently been applied for 
encapsulating nanoparticles and anticancer drugs. Few clinical experiments have been 
done to bring the concept into play for pharmacological experiments. Formulating LbL 
nanocapsules less than 200 nm size is crucial for effective IV delivery with improved 
bioavailability.
In Chapters 4, 5 and 6, washless LbL assembly with surface modification with 
poly ethylene glycol (PEG) tails has been used to encapsulate different forms of 
nanocores, soft mesocrystallline drug core, nanomiceller core, and nano structured lipid 
cores. The hypothesis is that when the particle circulates in the blood, the LbL assembly 
will act as a barrier between the drug core and the external environment. The PEG tails 
will inhibit blood protein from binding to them. These effects will significantly improve 
the colloidal stability, preserve the anticancer activity of the drug, improve the circulation 




Ultrasound technology has been an effective way to process or clean materials in 
medicine and also in industries. A Branson 1510 ultrasonicator (Branson Ultrasonics, 
US) was used to prepare the different nanocores followed by the LbL assembly and extra 
PEGylation.
3.2 Zeta-Potential Analyzer
A C-Plus Microelectrophoretic instrument (Brookhaven Instruments, Co.) was 
used to measure the hydrodynamic diameter and the surface charge of nanoparticles 
during each layer deposition of the LbL assembly. The instrument was calibrated using a 
standard sample from the manufacturer. For each measurement of the sample, 20 pL of 
the sample was diluted up to 2 mL by using the required solvent. The ^-potential was 
measured in the range of 200 mV to -200 mV. The ^-potential can be used for certain 
theoretical models, which can be further used for finding out the ionic concentration (C) 
per unit area of the particles (m2).
3.3 Electron Microscope
Two types of electron microscopes were used for the morphological analysis of 
nanoparticles: Scanning Electron Microscope (SEM) for surface morphology analysis
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and Transmission Electron Microscope (TEM) from Zeiss, Co., for confirming the LbL 
assembly on the nanocore. The SEM images showed the structural features of the 
particles. For each preparation, the drug particles were centrifuged and resuspended in the 
required solvent. A 2 mg/mL concentration of the sample was diluted 100 times in the 
same solvent. Then a small drop of it was put on a clean silicon slide. It was room-dried 
and then observed under SEM at 1.5 kV. While for TEM imaging the same diluted 
sample was dropped on a copper grid, then a negative stain was dropped, followed by 
removing the excess stain by a blotting paper. The sample was room-dried and seen 
under the TEM.
3.4 Quartz Crystal Microbalance
QCM-R with motional resistance monitoring (QCM200, Stanford Research 
System) is an effective method to measure the thickness and mass of each polyelectrolyte 
deposition per cm2 on the flat 5 MHz quartz crystal resonator. The quartz crystal, 
subjected to an electric impulse, resonates at a well-defined frequency. As a film is 
deposited on the crystal, the increase in mass decreases this frequency and increases the 
viscosity resistance. To perform this measurement, the crystal must be washed after each 
polyelectrolyte or film of different solution is deposited. The deposited mass is deduced 
from the Sauerbrey equation:
Af= ~C/  Am, Eq. 3-1
where, A/is the observed frequency change in Hz, Am is the change in mass per unit area 
in g/cm2, and Cf is the sensitivity factor of the crystal (56.6 Hz pg-lcm2 for a 5 MHz AT- 
cut quartz crystal at room temperature).
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3.5 High Performance Liquid Chromatography (HPLC)
An Agilent 1100 (Agilent Technologies) reverse-phase high performance liquid 
chromatography (RP-HPLC) was used. RP-HPLC is a process of chromatographic 
separation technique in which the stationary phase is a hydrophobic non-polar solid phase 
in the column (C-l 8), and a polar mobile phase. The maximum rate of flow used for 
analysis was 0.2 mL/min.
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CHAPTER 4
LAYER-BY-LAYER NANOENCAPSULATION OF 
CAMPTOTHECIN WITH IMPROVED ACTIVITY
This chapter describes the application of washless LbL assembly for 
encapsulation of the anticancer drug CPT as a soft core conjugated with BSA. The unique 
pH reversal step from 3 to 7.2 is performed to specifically preserve the active Lactone 
form of CPT. The morphological characterization was assessed through a particle size 
analyzer, SEM, and TEM; the drug chemical analysis was performed by UV-Vis 
spectroscopy; the LbL assembly architecture was verified by zeta potential and QCM 
studies. The in vitro release studies in PBS and FBS and the cell toxicity studies against 
brain glioblastoma cells are escribed. The sections in this chapter was published as: G. 
Parekh, P. Pattekari, C. Joshi, T. Shutava, M. DeCoster, T. Levchenko, V. Torchilin, Y. 
Lvov, “Layer-by-Layer nanoencapsulation of CPT with improved activity,” International 
Journal o f  Pharmaceutics, vo. 465, no. 1-2, pp. 218-227, April 2014. Sections 4.3.9, 4 is 
not included in the publication mentioned above. Results from this paper are included 
only in the dissertation.
4.1 Introduction
Among delivery methods for poorly soluble substances with antitumor activity, 
encasing drugs into micro and nanoparticles seems to be a promising strategy to design 
implantable devices or injected directly at the tumor site; low drug loading that can be
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achieved in such devices is compensated by prolonged release properties [80-82]. Several 
formulations based on nanoparticle technology [58,48,4, 83, 49] have been developed 
for oral or intramuscular injections, but only a few of them are intended for intravenous 
injection as albumin-based nanoparticles containing PTX (Abraxane®) [84, 85, 86]. 
Another strategy, namely, injectable nanocapsules based on crystalline core of poorly 
soluble anticancer drugs stabilized with a thin shell of bio polyelectrolytes assembled via 
Layer-by-Layer (LbL) assembly technique, was recently reported [11].
LbL assembly provides an opportunity to form a nano-thick coating in a 
controllable manner on the surfaces of variable curvature and size from interacting 
oppositely charged polyelectrolyte components [11, 87, 57, 35, 28, 31,29, 88]. Anchored 
to the core surface, the thin shell of hydrophilic polyelectrolytes allows exchange of 
excipients used on the core preparation. It concentrates nanocolloids without aggregation 
or recrystallization and supports their high stability in physiologically relevant buffers. 
Major advantages of LbL based formulation are a high, up to 70%, drug loading capacity, 
and an ease of further modifying the outer shell to enhance the stealth properties of the 
nanoparticles [11],
To intensify the preparation of LbL capsules on small, less than 200 nm cores, the 
washless LbL technique has been developed [11,19, 20]. Polyanions and polycations are 
sequentially added to drug nanocores in the minimal amounts that completely adsorb on 
the surface of the particles recharging them. No intermediate washing of non-reacted 
polyelectrolytes is needed in such an approach. This removal of washing steps minimizes 
the loss of all substances, like those in conventional centrifugation or filtration-based LbL 
technique using step-wise sample washing. High hydrophilicity of used polymers, block-
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copolymers of polyaminoacids with polyethylene glycol and polysaccharides, and also 
low molecular weight i.e. < 60 kDa of the shell wall components prevented colloidal 
aggregation during the LbL formation [11, 28, 31, 29, 88].
CPT combines low solubility in aqueous-based media with low stability of its 
active form, lactone, which easily hydrolyses into carboxylate at neutral and slightly 
alkaline pH [89-93]. Among other nanoparticulated formulations of CPT, such as 
polymer-based delivery systems, lipid, liposome and solid lipid nanoparticles, 
polyelectrolyte modified LbL-based nanocapsules of CPT seems to be a promising route 
to obtain a concentrated dispersion, 0.5 -1.0 mg/mL, stable in physiologically relevant 
buffers and that can be injected intravenously with minimal side effects. We expect that 
the LbL-coated CPT nanocapsules (Figure 4-1) will improve the chemical stability of 
CPT and preserve the active lactone form of the drug by reducing its hydrolysis to an 
inactive carboxylic form at neutral and alkaline conditions, especially in the presence of 
albumin. It makes such nano-formulation more active and less toxic for a living body due 




Figure 4-1: Scheme of CPT nanocapsules preparation [12].
4.2 Materials and Methods
4.2.1 Materials
CPT was obtained from LC Laboratories, USA. Heparin sodium salt (HEP), BSA, 
polystyrene sulfonate (PSS), polyethyleneimine (PEI), polyvinylpyrrolidone (PVP), 
Polysorbate 80, phosphate buffered saline (PBS), dimethyl sulfoxide (DMSO), and 
acetonitrile were obtained from Sigma-Aldrich and used as received. Fetal bovine serum 
(FBS) was obtained from Atlanta Biologicals, USA. Block-copolymers of poly-L-lysine 
with polyethylene glycol (PLB) of different molecular weights (PLL[16kDa]-b- 
PEG[5kDa] (PLB16-5) and PLL [16kDa]-b-PEG[20kDa] (PLB16-20)) were obtained 
from Alamanda Polymers, USA; mPEG5kDa-Succinimidyl Valerate (SVA) and 
mPEG20kDa-SVA were obtained from Laysan Bio, Inc., USA. For cell culture studies, 
rat brain glio-blastoma cells CRL 2303 were obtained from American Type Culture 
Collection (Manassas, VA), DMEM from ATCC-30-2002, Thiazolyl Blue tetrazolium 
bromide, 98% (MTT) from Alfa Aesar, USA.
4.2.2 Drug nanocapsule preparation
4.2.2.1 Core preparation
Under continuous sonication, 200 pL of freshly prepared CPT solution in DMSO 
(7 mg/mL) was added to 2.58 mL of PBS buffer (pH 3) containing 0.64 mg/mL BSA and
1.44 mg/mL PVP and further sonicated for 15-20 min.
To optimize nanoparticle preparation conditions, in one series of experiments, the 
concentration of BSA in the mixture was varied from 0.35 to 2.50 mg/mL at C(PVP) =
1.44 mg/mL, while in another, the concentration of PVP was varied from 0 to 2.2 mg/mL 
and the C(BSA) was fixed at 0.64 mg/mL. Upon sonication, C, potential (in DI water) and
39
hydrodynamic diameter (in PBS buffer, pH 3) of the nanocores were measured using a 
ZetaPlus Brookhaven instrument.
4.2.2.2 Polvelectrolvte shell formation on nanocores
By alternating the addition of 20 pL aliquots of HEP or PLB16-5 (both 60 mg/mL 
in acidic PBS, pH 3), 3.5 pairs of the polyelectrolyte layers were deposited on the cores, 
with heparin being the outermost layer. Each polyelectrolyte solution was added to the 
nanoparticles’ dispersion under constant sonication that continues for another 30 seconds. 
The obtained dispersion was kept for 5 min before the addition of the next 
polyelectrolyte. No intermediate separation of nanoparticles from supernatant or rinsing 
the nanoparticles with buffer was made. The assembly of polyelectrolytes was followed 
by the measurements of C, potential (in DI water) and hydrodynamic diameter of the 
nanoparticles. The nanocapsules with HEP as the top layer (-20 mV) were separated by 
centrifugation at 10,000 rpm for 10 min (Eppendorf 5804R centrifuge) and redispersed in 
the same volume of PBS buffer, pH 7.4. More pairs of layers were assembled at pH 7.4 
using 60 mg/mL solutions of polyelectrolytes by sequentially adding 20 pL aliquots of 
Hep and a copolymer of PEG and PLL (PLB16-5 or PEG16-20).
4.2.2.3 PEGvlation of polvelectrolvte shell
The powder of mPEG5kDa-SVA or mPEG20kDa-SVA was directly added to the 
dispersion of nanoparticles with a positively charged outermost layer (PLB16-5) in PBS 
buffer at pH 7.4 to achieve the PEGylator concentration of 40 mg/mL and the mixture 
was vigorously shaken and sonicated for 30 s to dissolve the PEGylator. The dispersion 
was kept for 10 h at 4° C. The nanoparticles were separated by centrifugation at 14,000
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rpm (Eppendorf 5804R centrifuge) for 10 min and the pellet was resuspended in PBS, pH 
7.4.
4.2.3 Influence of PVP on the amounts of polvelectrolvtes needed for charge 
reversal
In this series of experiments, the dispersions of CPT cores were obtained as 
described above but the concentration of PVP varied from 0 to 2.2 mg/mL in different 
batches. Each polyelectrolyte was stepwise added to the dispersions containing a given 
amount of surfactants in small aliquots, 20 pL of a 6 mg/mL solution in PBS, pH 3.0.
This was continued until the C, potential of the nanoparticles reached a value of ±25 mV. 
The amount of polyelectrolyte needed to complete one layer was calculated as a sum of 
that added in all aliquots. Then, the polyelectrolyte with an opposite charge was added in 
a similar way. Two pairs of layers were assembled for each dispersion.
4.2.4 Analytical techniques
4.2.4.1 Amount of BSA adsorbed on nanocores
FITC-labeled BSA was used to evaluate the amount of BSA adsorbed on CPT 
nanocores at different stages of shell preparation. The concentrations of BSA-FITC from 
0.24 to 2.50 mg/mL were used for core preparation; a HEP/PLB16-5 bilayer was coated 
by adding 20 pL of 60 mg/mL solutions of each polyelectrolyte to the obtained 
dispersion at pH 3 as described above. In another series of experiments, 3.5 HEP/PLB16- 
5 bilayers were assembled on nanocores at pH 3. The nanocapsules were separated from 
supernatant by centrifugation, washed once with PBS buffer pH 7.4, redispersed in the 
buffer, and then coated with one more PLB 16-5/HEP bilayer. The nanoparticles were 
separated from the supernatant, and the concentration of BSA-FITC in the supernatant
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was estimated using FITC absorbance at 490 nm (Agilent 5893 UV-vis 
spectrophotometer).
4.2.4.2 Drug concentration in nanoparticles
The content of CPT in the obtained dispersions of nanocapsules was measured 
after extraction of the drug with a 1:1 :: DMSO: acetonitrile mixture [90]. The insoluble 
remains of polyelectrolyte shell were removed from the medium by centrifugation. The 
concentration of CPT in the solution was measured using the drug absorbance band at 
381 nm (extinction coefficient, e = 1.92 x 104 M^cm'1) [89-93]. The BSA concentration 
was measured in PBS, pH 7.4, at 280 nm, e = 171.6 M^cnT1.
4.2.5 Characterization of CPT chemical stability
The chemical stability of CPT in the core of (HEP/P 16-5)5.0 nanocapsules was 
studied both in PBS buffer and the buffer with BSA (25 mg/mL) at pH 3, 5, 7.4, and 9 
and at room temperature (22° C). CPT dissolved in DMSO was used for comparison. The 
CPT nanocapsules were dispersed in a medium at the concentration of 0.04 mg/mL. At 
different time intervals, 20 pL aliquots of the mixture mentioned above were added to 
1.98 mL of a 1:1 DMSO: acetonitrile solvent [90] and absorbance of the extract at 354 
nm was measured.
The lactone fraction at time t (LF) was calculated as the percentage of the total 
drug content:
LF =  -— Ahn m ~At------x  100%. Eq. 4-1
AUtWi ~ *urb«ylit»
where Aiactone and ACart>oxyiate are absorbances of the solutions containing CPT only in the 
lactone and carboxylate form, At is current absorbance of the extract. The percentage of
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lactone CPT that remains in the cores obtained at different pH was estimated using the 
ratio of absorbances at 366 nm and 381 nm at a given pH and at pH 3.
pHs
LF =  X 100%. Eq. 4-2
4.2.6 Characterization of colloidal stability of CPT nanoparticles
A dispersion of CPT nanocapsules with a shell of a given architecture was 
concentrated to 0.5 mg/mL in PBS buffer and the hydrodynamic diameter of the 
nanoparticles was measured over 7 days. During the test, all samples were kept at 22° C.
4.2.7 Quartz crystal microbalance: Analysis of PLB 16-5/HEP film thickness. 
PEGvlation and binding of serum protein
The films of PLB 16-5 and HEP were formed on flat gold working surfaces o f 5 
MHz quartz crystal resonators from 0.5 mg/mL polyelectrolyte solutions in water in a 
liquid flow cell and the film assembly was followed by QCM-R technique with motional 
resistance monitoring (QCM200, Stanford Research System) [94-96]. After adsorption of 
each polyelectrolyte, the cell was rinsed with DI water. After assembly of a desired 
number of PLB 16-5/HEP layers on a resonator, a 50 mg/mL solution of mPEG5kDa- 
SVA or mPEG20kDa-SVA in water was injected into the cell for 24 h. The unreacted 
PEGylator was removed from the cell by rinsing it with water. The attachment of proteins 
from FBS was monitored for 20 min, and finally the cell was washed with an excessive 
amount of water. The shifts of resonance frequency AF and motional resistance AR were 
calculated for a resonator with a film immersed in water relatively to the empty resonator. 
The mass of the deposit was calculated using the Sauerbray equation for rigid films [94- 
96].
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4.2.8 Characterization of release study
The release of CPT from the LbL-coated capsules with and without additional 
PEG layer was studied in PBS buffer, pH 7.4 or 5.0, supplemented with 2% w/v 
Polysorbate 80, or in FBS. The solubility of CPT in PBS-2% w/v Polysorbate 80 is ca.
1.6 pg/mL at pH 7.4 and 0.9 pg/mL at pH 5. The solubility of CPT in FBS is ca. 6.7 
pg/mL. The dispersion of the nanoparticles under study was added to the release medium 
which was continuously stirred at 1050 rpm (Eppendorf 5804R centrifuge) at 37.4 0C. 
With 0.5-12 h intervals, 1 mL/2 mL aliquots were withdrawn from the mixtures of 10 
mL/30 mL, as total volumes for release in PBS/FBS respectively. They were then 
replaced with the same volumes of fresh medium. The release was followed for 24 h. The 
nanocapsules with undissolved CPT were separated from the aliquots by centrifugation. 
The concentration of CPT dissolved in supernatant was estimated by UV-vis 
spectroscopy using the absorbance peaks of CPT at 370 nm (in PBS with 2% w/v Tween 
80, e = 4.0 x 104 M'1 cm'1). All experiments were run in triplicates and the data were 
averaged. In the control experiment, CPT dissolved in DMSO was used.
4.2.9 TEM sample preparation
10 pL of concentrated dispersion of CPT nanoparticles in DI water was dropped 
on a copper grid. After 30 s it was stained with 10 pL of 1% ammonium molybdate. The 
excess amount of the stain was absorbed by a tip of filter paper. The sample was allowed 
to air dry for half an hour. The TEM images were taken on a Zeiss EM912.
4.2.10 In vitro cell culture study
Cell culture: Rat brain glio-blastoma cells CRL2303 (American Type Culture 
Collection) were cultured in 24 well plates with DMEM medium supplemented with 10%
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FBS (ATCC) and penicillin/streptomycin. It was maintained at 37° C in a 5% C02 
incubator. The incubation was done overnight to get a cell density of 40,000 cells/mL for 
MTT assay and 15,000 cells/mL for morphological studies [97, 98].
Treatment o f cells: After required incubation, the cells were treated with varying 
concentrations (0.01-10 pM) of CPT as nanoparticles coated with (HEP/PLB 16-5)7 
bilayers and (HEP/PLB 16-5)7 bilayers -mPEG shells, or free drug. To obtain a stock 
solution of free drug, its powder was sonicated for 15 min in PBS, pH 7.4, and then 
centrifuged out to obtain a particle-free supernatant. It had the CPT concentration of 26.9 
pM and a LF value of 96.4%. For positive control, the treatment of cells was done with 
50 pg/mL copper (II) oxide nanoparticles (CuO NPs) that have high cell toxicity [97]
[98]. The morphological features were seen under an Olympus 1x51 inverted microscope. 
MTT cell viability assay [99] was performed at two time points, 16 and 40 h. Four 
hundred pL of 1.25 mg/mL, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) solution was made in Locke’s solution at pH 7.2. It was initially pre­
warmed for 10 min in the incubator chamber. The culture medium from each well was 
replaced with the same volume of MTT solution. The wells were covered with aluminum 
foil and then incubated for 1 h. Then the medium was removed carefully, without 
expiration of the MTT formazan precipitates. The formazan precipitates were solubilized 
in 200 pL of 91% iso-propyl alcohol. Their absorbance was measured at 570 nm in a UV 
plate reader Multiskan GO, Thermo Scientific. The cell viability (CV) was calculated 
with respect to the average cell viability of the negative control:
CV =  - E  x  100%. Eq. 4-3
n A y i tnin t l  w control
4.3 Results and Discussion
4.3.1 Optimization of soft nanocore preparation conditions
4.3.1.1 Influence of pH
The hydrodynamic diameter of prepared CPT cores changes drastically with the 
pH used (Figure 4-2a). It reaches a few tens of micrometers in the pH range from 4 to 6. 
In this range, the particles have a negative C, potential, which is not sufficient for colloidal 
stability of the dispersions, whereas the core size at pH 7.4 is close to 400 nm as their 
surface charge goes beyond -20 mV. The cores exhibit the particle size of 140± 20 nm at 
pH 3. Despite the CPT nanoparticles are only slightly positively charged at this low pH, 
stable nanocolloids are formed.
The CPT cores were prepared under different pH conditions to evaluate the 
fraction of the active lactone form of the drug that retains after 20 min of intense 
sonication in the presence of BSA and PVP. The concentration of the lactone form in the 
obtained dispersion of nanoparticles reduces gradually as the pH increases from 3 to 9 
(Figure 4-2b). The active lactone form of CPT and its derivatives is easily hydrolyzed 
into less active and toxic carboxylic form [89-93] and its preservation during preparation 
and storage is of high priority. Therefore, the preparation of CPT cores at pH 3 is the 
most reliable method to obtain smaller than 200 nm CPT particles preserving the highest 
content of its active lactone form.
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Figure 4-2: a) Influence of pH on hydrodynamic diameter and C, potential of CPT cores, 
b) The content of the lactone form in the CPT cores prepared at different pH.
4.3.1.2 Amount of BSA bound to CPT nanocores
The amount of BSA-FITC bound to CPT cores coated with a Hep/PLB16-5 
bilayer at pH 3.0 is 1.05 ± 0.03 mg/mg and remains the same for all concentrations of 
BSA above 0.64 mg/mL (Table 4-1). At this concentration, more than 90% of the added 
BSA-FITC binds to the core surface. If a smaller concentration of BSA is used, the 
protein is completely bound to the core, but the apparent diameter of nanoparticles 
increases sufficiently.
After changing pH from 3 to 7.4, a partial desorption of BSA-FITC from CPT 
nanocore’s surface takes place (Table 4-1). At pH 7.4, the charge of BSA (pi = 5 [100]) is 
reversed to a negative value affecting adsorption of the protein. However, due to mainly 
hydrophobic interaction between CPT and BSA [101-103] and a variety of possible 
polyelectrolyte binding sites on the protein [80], a sufficient amount of the protein 
remains bound to the surface and to the LbL shell. The concentrations of BSA-FITC 
higher than 0.64 mg/mL lead to micrometer-sized particles during further LbL assembly 
at pH 7.4, while the nanocapsules prepared at a 0.64 mg/mL BSA concentration give
47
stable colloids up to 24 h with a nanoparticle diameter of 178 nm. Therefore, these 
conditions are considered to be the optimum parameters for the core preparation protocol.




C (BSA)/C (CPT), 
mg/mg




coated with (Hep/PLB16-5) shell, pH 3.0
0.35 0.62 97±3 254±15
0.64 1.16 91±3 167±12
1.28 1.01 43±2 180+15
1.90 1.13 30+2 303±14
2.50 4.96 100±3 1152±56
coated with a (Hep/PLB 16-5)4.5 shell, pH 7.4
0.24 0.24 64±2 245+2
0.36 0.36 69±3 220+4
0.64 0.69 54±2 178±2
4.3.1.3 Influence of Poly vinvl pvrrolidone (PVP)
PVP was used as an excipient for the formulation to improve colloidal stability of 
the dispersion of CPT nanoparticles. As the concentration of PVP in the core preparation 
medium increases, the hydrodynamic diameter of CPT cores goes through a maximum at 
0.7 mg/mL PVP concentration and then decreases significantly (Figure 4-3). It reaches 
200+20 nm over the 1.4-2.2 mg/mL range, which was further used to get optimal size on 







Figure 4-3: Influence of PVP concentration on hydrodynamic diameter of CPT core (1) 
and amounts of polyelectrolyte needed for recharging their surface upon adsorption: 2 -  
first step: HEP on BSA-stabilized CPT cores; 3 -  second step: PLB 16-5 on CPT/HEP 
nanoparticles; 4 -  third step: HEP on CPT/HEP/PLB16-5 nanocapsules, and 5 -  fourth 
step: P16-5 on CPT/(HEP/PLB 16-5) 1.5 nanocapsules. pH 3.0.
The feature of the current approach is the formation of polyelectrolyte shell on the 
BSA-stabilized particles directly in the medium used for preparation of CPT cores that is 
in the presence of polyvinylpyrrolydone. In this series of experiments, CPT cores were 
produced at different PVP concentration varying from 0 to 2.2 mg/mL. Besides the 
already mentioned effect of the excipient on the core size, we observed some dependence 
of the amounts of polyelectrolytes needed for £ -potential reversal on the concentration of 
PVP (Figure 4-3). The light increase of the polyelectrolyte amounts needed for each layer 
in more concentrated PVP solutions correlates well with smaller apparent size and higher 
specific surface of the cores. The difference between the amounts of Hep needed to 
complete a charge reversal in the first and the third layer (curves 2 and 4) displays the 
difference in the adsorption conditions on BSA and PLB 16-5 layers.
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In all further experiments, each polyelectrolyte was added in one aliquot in the 
amount of ~ 0.7-0.8 mg per 1 mg of CPT that corresponds precisely or somewhat higher 
than the values in Figure 4-3. Therefore, a small amount of each polyelectrolyte remains 
in the supernatant. As shown previously, such excessive polyelectrolytes react with 
alternately charged polymer added on the next stage forming 20-50 nm Hep/PLB 16-5 
complexes that float free in the solution or adsorb on the nanoparticles’ surface.
4.3.2 LbL assembly
Stable nanocapsules of CPT with a 140 nm diameter were prepared at pH 3.0 as 
described above. However, to be injectable the dispersion should be reconstituted in a 
physiologically relevant medium with pH 7 in isotonic PBS buffer or 0.9% sodium 
chloride solution.
The advantage of LbL assembly of polyelectrolytes over other surface 
modification techniques is the possibility of forming several pairs of layers initially at 
one pH and further shift pH to another value and finish the coating [87, 57, 35]. We used 
this approach to deposit 3.5 HEP/PLB 16-5 bilayers at low pH to stabilize the colloids of 
the desired diameter with the highest content of lactone, and further added several layers 
at pH 7.4.
Previously, it was shown that to avoid complications related with material lost 
and nanoparticles aggregation during centrifugation-based assembly, nanoparticles can be 
coated with polyelectrolytes using the washless LbL technique directly in the presence of 
uncharged excipients [11]. Utilization of block-copolymers of polyamino acids and 
polyethylene glycol and polysaccharides of low molecular weight allows preserving 
colloidal stability of the nanoparticles. The polyelectrolytes are added in the amounts that
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are needed to reverse ^-potential to an opposite value as high as 20 mV, thus allowing 
building up of the LbL shell.
The CPT cores were found to be positively charged at pH 3 (Figure 4-4). Their 
positive charge is caused by BSA adsorbed on the surface [100]. The minimum amounts 
of BSA which is only sufficient to support colloidal stability of the nanoparticles but 
leaves almost no free protein in the supernatant on the core preparation stage was 
utilized. Thereby, BSA simultaneously works as a surfactant and the first layer in the 
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Figure 4-4: Reversal of ̂ -potential value of CPT nanoparticles in the process of washless 
LbL assembly of polyelectrolyte shell.
The alternation of positive and negative values of ̂ -potential confirms the shell 
formation on the surface of the nanoparticles (Figure 4-4) at pH 3. Three and a half 
HEP/PLB 16-5 bilayers allowed to obtain CPT nanocapsules of about 150 nm in size and
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well dispersed in PBS at pH 3. In addition, 7.0 bilayers of (HEP/PLB 16-5) were 
deposited in PBS at pH 7.4 to stabilize the colloids at this physiologically relevant 
condition.
TEM images of CPT nanoparticles coated with a (HEP/PLB16-5)7.0 bilayers shell 
(Figure 4-5) show particles with a uniform spherical shape. The polyelectrolyte shell 
material is not distinguishable from the organic core because it has the same electron 
density.
Figure 4-5: TEM image of CPT nanoparticles with a (HEP/PLB16-5)7.0 shell.
4.3.3 OCM analysis of capsule wall thickness, enhanced PEGvlation and serum 
protein attachment
The thickness of the nanocapsule wall was evaluated by QCM-R technique. The 
mass of polyelectrolyte film deposited on the flat surface of a quartz resonator was 
recalculated from its frequency decrease using the Sauerbray equation [94-96]. The 
thickness of 4.5 and 7.5 (PLB16-5/Hep) bilayer films is ca. 5.2 and 7.5 nm (Table 4-2). 
The difference between the films with 4.5 and 7.5 bilayers in attachment of PEG upon the
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treatment with a PEGylator is negligible. Therefore, it is safe to assume that only film 
outermost amine groups interact with the substances.
Table 4-2: PLB 16-5/Hep thickness, amount of attached PEG.
Assembly Bilayers(n)
dF, Hz Absorbed mass, ug/cm2 Thickness*, nm
LbL film
(PLB16-5/Hep)n 7.5 51.2+10.7 0.910.2 7.54.5 35.0±5.6 0.610.1 5.2
Attached PEGylator on (PLB16-5/HEP)n, Cone. mPEG-SVA=50 mg/mL
PEG 5kDa 7.5 41.1±7.3 0.710.1 5.8
PEG 5kDa 4.5 49.4116.1 0.910.3 7.5
PEG 20kDa 7.5 70.3 1.2 10
PEG 20kDa 4.5 58.0 1.0 8.3
* - using 1.2 g/cm3 fi m density [94-96].
The mass of mPEG20kDa attached to the film is ~ 1.2-1.7 times exceeding that of 
mPEG5kDa. This mass corresponds to the PEGylation degree that corresponds to the 
maximum surface coverage by PEG tails. Although many amine groups remain unreacted 
on the surface, the further PEG attachment is hindered by neighboring PEG tails. The 
mass of these attached PEG corresponds to a layer with an apparent thickness of 6-10 nm.
The PEGylation significantly decreases the attachment of serum proteins to a 
(PLB16-5/Hep)n film (Table 4-3). The AF shift which is proportional to the deposited 
mass is 5-11 Hz for PEGylated surfaces vs. 40 Hz for surfaces without enhanced 
PEGylation.
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PEGylation 4.5 50.9 0.89 7.4
PEG 5kDa 7.5 5.7 0.1 1.7
PEG 5kDa 4.5 4.7±4.2 0.1 1.7
PEG 20kDa 7.5 11.0 0.2 0.8
PEG 20kDa 4.5 11.0 0.2 5.9
* - using 1.2 g/cm3 film density [94-96].
4.3.4 Colloidal stability of nanocapsules
One of the major parameters of nanocapsule applicability for intravenous 
administration is their colloidal stability in physiologically relevant buffer and the size 
remaining < 200 nm.
The CPT nanocores coated only with BSA have low colloidally stable for 2 h in 
PBS buffer both at pH 3 and 7.4. The samples with 5 bilayers of (HEP/PLB 16-5) shell 
(positive outermost layer) had a hydrodynamic diameter within 130±10 nm for at least 7 
days, while the size of the sample coated with 7 bilayers of (HEP/PLB 16-5) increases to 
300 nm (Figure 4-6a). The CPT colloids with a shell that have negative HEP layer on the 
top are to some extent more stable than that with positive PLB 16-5 (Figure 4-6b). One 
possible explanation is that HEP macromolecules deposited atop PLB 16-5 act as spacers 
between PEG tails and keep them straighter than that with PLB 16-5 on the top, thus 
providing better steric hindrance.
However, if a PLB 16-5 terminated shell is additionally PEGylated, the obtained 
nanoparticles had the hydrodynamic diameter of 123±2 nm for 48 h, and after 7 days
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their size increased only by 70 nm, proving that the availability of free amine groups on 
the surface of CPT nanocapsules is the main reason of their colloidal instability. Attached 
PEG chains increase nanoparticles hydrophilicity and therefore stability of the colloids.
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Figure 4-6: Colloidal stability of nanocapsules in PBS buffer, pH 7.4 with varying: a) 
number of bilayers: 1 - (Hep/PLB 16-5)5.0 and 2- (Hep/PLB 16-5)7.0 ; b) outermost layer: 
3 - (Hep/PLB 16-5)5.0 and 4 -  (Hep/PLB16-5)5.5; c) PEGylation: 5- (Hep/PLB 16-5)5.0 
and 6 - (HEP/PLB 16-5)5.0/mPEG5kDa; d) molecular weight of PEGylator on a 
(Hep/PLB 16-5)8.0 shell: 7 -  mPEG5kDa and 8 -  mPEG20kDa.
At the same time, apparent stability of the CPT colloids that are additionally 
PEGylated with mPEG20kDa-SVA is not as good as that of colloids treated with 5 kDa 
PEGylator and even worse than the expected stability of PLB 16-5 terminated 
nanoparticles. This difference might be caused by increasing viscosity in the vicinity of 
the nanoparticle surface caused by high molecular weight PEG chains slowly protruding
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into the solution with time. Long irregular PEG chains can also support self-assembly of 
the nanoparticles into more complex structures [104, 105].
One can conclude that the best encapsulation is for 5 bilayers with extra 
PEGylation of shorter length PEG tails, 5 kDa. To make a slower release, we will further 
make the LbL wall thicker by adding two more bilayers onto the shell.
4.3.5 Chemical stability of CPT in nanocapsules at different pH
CPT has two forms, lactone and carboxylate. Lactone is less toxic and a more 
active form of CPT for inhibiting Topoisomerase I [106-108]. The lactone group of the 
substance easily hydrolyses to carboxylate at neutral and slightly alkaline conditions.
In PBS, at all studied pH except pH 9, the lactone form of CPT in nanocapsules 
was preserved at least for 17 h with a light decrease of its content to 97-98% during next 
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Figure 4-7: Chemical stability of CPT in the nanocapsules (a,b) and free CPT (c,d) in 
PBS (a, c) and in PBS with 25 mg/mL BSA (b, d). pH: 1- 3.0; 2-5.0; 3- 7.4; 4- 9.0.
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At the same time, free CPT added to the release medium as a solution in DMSO 
degrades faster at all pH, including pH 3-5 (Figure 4-7c). In the presence of 25 mg/mL 
BSA, lactone in CPT nanocapsules is stable over a wide range of pH, including pH 9.0 
(Figure 4-7b), LF is -96% after 24 h. Moreover, the lactone form is more preserved than 
that in PBS alone (Figure 4-7a). The improved chemical stability of CPT in LbL capsules 
makes such formulation less toxic than free CPT.
4.3.6 Release of CPT in PBS and FBS
In PBS buffer supplemented with 2% w/v Polysorbate 80, an initial burst of drug 
released into the medium leads to 25-30% dissolution of nanoparticles for 1.1-1.6 pg/mL 
of CPT, and 60% release for 0.5 pg/mL was observed. It is followed by slowing down the 
drug dissolution during the next 3 h (Figure 4-8a). After that, the released percentage of 
drug did not change significantly. For the lowest concentration of CPT, 0.5 pg/mL, that is 
eighteen times lower than the CPT solubility (ca. 9.4 pg/mL), the release reaches the 
maximum of ~ 70% after 24 h. No sufficient difference in release profile was observed at 
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Figure 4-8: Release of CPT from nanocapsules with a (HEP/PLB 16-5)5 shell in PBS 
with 2% w/v Polysorbate 80, (a) cumulative release of CPT, C (CPT), pg/mL: 1- 0.5, 2- 
1.1,3-1.6. (b) lactone fraction remaining in the release medium at pH 7.4 and 5.0 as a 
function of time. C (CPT) = 1.6 pg/mL. *P < 0.01.
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However, after the drug is being released from the nanocapsules at pH 7.4, a slow 
hydrolysis of the lactone form of CPT to the carboxylic one takes place. After 6 h, up to 
16% of the drug is converted to the carboxylic form (Figure 4-8b). On the other hand, up 
to 96% of released CPT retains the lactone form after 24 h if released at pH 5.
The release profile of CPT from (HEP/PLB 16-5)5 nanocapsules in FBS differed 
from that in PBS (Figure 4-9). An initial fast release up to 85% takes place within the 
first 30 min. However, the concentration of CPT in the release medium decreases and the 
apparent percent of released drug diminishes to 25-30%. Apparently, this trend was due 
to initial aggregation of non-extra-PEGylated nanoparticles with the serum proteins. It 
has a lower CPT solubility limit in FBS (6.7 pg/mL) as compared to that in PBS. Similar 
release profiles were obtained for different concentrations of CPT nanocapsules 
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Figure 4-9: Detectable CPT concentration depending on time due to release from 
(HEP/PLB 16-5)5 (1) and (HEP/PLB 16-5)5/mPEG5kDa (2) nanocapsules in FBS (a) and 
lactone fraction retained in the released medium (b) as a function of time. C(CPT) = 
2.27pg/mL.
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It was assumed that the released CPT molecules interact with proteins from the 
bovine serum. As the time of release increased, a growing volume of the sediment was 
observed upon separation of nanoparticles from the release medium by centrifugation. A 
sufficient part of the precipitate was found to be the proteins. The interaction with CPT 
seems to enhance aggregation of the serum proteins or their attachment to the walls of 
polyelectrolyte capsules.
The hydrophilic PEG layer formed on the surface of nanocapsules after treatment 
with mPEG-SVA shields them from the FBS proteins, thus minimizing their attachment 
and stabilizing the colloid in FBS. The initial release of CPT from the nanocapsules with 
enhanced PEGylation attains only 40% of the drug after 1 h, and then almost a linear 
increase of CPT concentration in the release medium was found (Figure 4-9). After 24 h, 
the released amount of drug reaches 60%. The apparent thickness of the extra PEG layer 
is comparable with the thickness of (PLB16-5/HEP)7.5 bilayers shell beneath it (Table 
4-2); therefore, a lower initial burst and prolonged time of release for the treated capsules 
are not surprising.
Apart from the much higher initial CPT release rate in the serum, the hydrolysis 
of the drug in the serum is also faster. For nanocapsules without enhanced PEGylation, 
the highest fraction of the lactone form, -0.9, was observed in FBS immediately after the 
initial burst, and then it decreases almost to 0.1 (Figure 4-9b). The difference in the 
hydrolysis rates in PBS and the serum can be related to the presence of a high 
concentration of albumin that accelerates the conversion of lactone to carboxyl [89-93]. 
For the sample with an extra PEGylated surface due to a much lower initial CPT release 
rate, the lactone fraction reaches its maximum after 3 h, indicating that at the earlier
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stages lactone interacts with the serum components and hydrolyses faster than it 
accumulates in the tumor cells. Due to the prolonged character o f release from the 
PEGylated nanocapsules, a new portion of lactone CPT is supplied into the supernatant 
during a long period of time, thus supporting its high relative concentration.
4.3.7 In vitro cell culture studies
The treatment of CRL2303 glioblastoma cells with both free CPT and 
nanocapsules with extra PEGylated shell causes prominent changes in their morphology 
that indicate a disappearance of cellular processes, while after the addition of comparable 
volume of PBS buffer the cells proliferate (Figure 4-10). After 40 h, the treatment with 
CPT led to clear disruption of cell membranes and necrosis of the cells.
Figure 4-10: Effect of free CPT (2 and 3) and CPT nanocapsules with (HEP/PLB 16- 
5)7/mPEG5kDa shells (4 and 5) on Rat brain glio-blastoma cells after 16 (upper row, a) 
and 40 h (lower row, b) treatment. 1) Negative control (PBS buffer), 2 ,4) 1.0 pM, 3, 5) 
10.0 pM. Images shown are representative of multiple wells (> 6) and multiple platings 
of cells for each condition tested. In collaboration with Dr. M. DeCoster, Louisiana Tech 
University, Ruston, LA.
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4.3.8 Effect of CPT nanocapsules on glioblastoma cells viability
Both CPT nanocapsules and free drug inhibit CRL2303 glioblastoma cell growth 
after 16 h of incubation; the decrease of cell viability depends on the applied 
concentration of CPT (Figure 4-11). The prolongation of the incubation up to 40 h 
increases the effect except for the case of 10 nM free drug that has been apparently 
hydrolyzed in the course of long cell incubation. The nano-formulation cytotoxic effect is 
mostly observed in the case of medium drug concentration, 100 nM (circled in the Figure 
4-11). For 100 nM CPT nanocapsules, a clear delayed effect is observed, with a decrease 











Figure 4-11: Effect of different concentrations of free CPT, and CPT nanocapsules with 
(Hep/PLB 16-5)7 and (Hep/PLB16-5)7/mPEG5kDa shells on CRL2303 glioblastoma cell 
viability. Data shown are representative of multiple wells (> 6) and multiple platings of 
cells for each condition tested. The percentage values of lOOnM are indicated. In 
collaboration with Dr. M. DeCoster, Louisiana Tech University, Ruston, LA.
The difference between cell growth inhibition activities of CPT nanocapsules with 
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corresponding ICso values are ca. 103.8 and 103.5 nM (Appendix A, Figure A-2). At the 
same time, when free CPT is less active, ICso is ca. 146.3 nM. We presume that after free 
CPT is added to the cell culture medium, a sufficient part of the drug is quickly 
hydrolyzed into less active carboxylic form, while the lactone CPT in nanocapsules is 
preserved and releases slowly in the course of the cell incubation.
4.3.9 Prevention of BSA loss from the core
In order to improve CPT loading capacity, we slightly modified the existing 
method as later mentioned. The nanocores of the CPT were formed as per the previous 
protocol. The LbL assembly of HEP/PLB 16-5 on the CPT nanocores was changed with a 
total number of 4 bilayers. Now the outermost layer deposited on the CPT nanocore was 
PLB16-5 at pH 3. Then the nanoparticles were washed once using centrifugation at a 
speed of 11,000 rpm (Eppendorf 5804R centrifuge) for 10 min and resuspended in PBS at 
pH 7.4. Furthermore, another two bilayers were deposited at pH 7.4 to form the entire 
shell composition with a total of six bilayers of HEP/PLB 16-5. The PEGylation step was 
the same as the earlier process. See Table 4-4.
Table 4-4: Zeta potential values before and after washing step after 4 bilayers.
Description pH Zeta %BSA
potential, mV in core
CPT- (hep/PLBi6-5)4.o 3 14±2 100
CPT-(hep /PLB 16-5)4.0 7 -7±4 -
CPT-(hep/PLB 16-5)4.0 / (hep /PLB 16-5)0.5 7 -25±5 -
CPT-(hep /PLBi6-5)4.o / (hep /PLBi6-s)2 7 14±2 96.7
CPT-(hep /PLB 16-5)4.0 / (hep /PLBi6-s)2/mPEG5kDa 7 1±1 77.8
CPT-(hep /PLB 16-5)3.5 / (hep /PLB 16-5)3.5 / mPEGskOa 7 3±2 56
After resuspension of nanoparticles from pH 3 to 7.4, zeta potential was measured 
as -7±4 mV. It was observed the release of BSA due to change in the pH. The change in
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zeta potential after switching the pH can be explained as re-deposition of BSA on the 
outermost layer of PLB16-5. See Table 4-4. In the usual method, the loading capacity of 
the CPT was approximately 56%. Due to change in outermost layer during pH change led 
to increase in loading capacity of CPT to -76% (Figure 4-12a). The particle size was 
measured ca. 210±2 nm and the lactone fraction (LF) was restored to LF -  0.998 after 3 
days (Figure 4-12a). The percentage of lactone fraction of the CPT in the core was 
estimated by formula (2) in Section 4.2.5.
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Figure 4-12: (a) % CPT loading and lactone fraction (LF) for 3 days study; (b) The 
colloidal stability of sample after extra PEGylation for (1) prior suspended, (2) pre­
suspended in PBS pH7.2 just before taking reading.
The reduction of loss o f BSA was also confirmed by the QCM studies. See 
APPENDIX A, Table A-l. In changing the outermost layer from HEP to PLL during pH 
change from 3.0 to 7.2, a significant loss in mass deposition is seen. There is mass loss of 
-0.866 pg/cm2 for HEP at the outermost layer and a mass gain of 0.618 pg/cm2 for PLL. 
This clearly indicates that the new approach has reduced the BSA loss and thus CPT drug 
loss from the core.
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The colloidal stability of such extraPEGylated LbL coated softcores after 7 days 
of study was observed to be 172±2 nm by taking immediate reading from the dispersion, 
and was 210±2 nm after keeping it suspended in the dilution of 100X in PBS pH 7.2 
(Figure 4-12b).
4.4 Conclusion
The objectives of using LbL formulation technique to encapsulate CPT were to 
preserve the lactone form of the drug; to attain < 200 nm mono-dispersed stable colloid 
dispersion at a high concentration of 0.5 mg/mL; to get a sustained release of the drug for 
at least 24 h with good lactone fraction and, finally, to have a better in vitro cancer cell 
growth inhibition effect than the uncoated CPT drug.
160 nm capsules were formulated with CPT in the core and BSA covering it, 
followed by a 7-8 bilayer of alternating anionic heparin (HEP) and cationic PEGylated 
polylysine (PLB 16-5). By attaining non-washing LbL assembly at two pH values 
(starting from lower pH 3 to preserve lactone form and proceeding at pH 7.4), 
nanocapsules were formulated with a loading capacity of approximately 60 w % and as 
high as 99% lactone CPT fraction. Colloidal stability of the nanocapsules was improved 
by incorporating mPEG 5 kDa tails on the outermost layer of PLB 16-5. The 
encapsulation of the CPT in the shells of polyelectrolytes modified with PEG reduces the 
rate of hydrolysis of lactone to carboxylic form compared with free drug at neutral and 
alkaline media. The modification of the nanocapsule’s outer surface with additional 
mPEG 5 kDa tails increases protein-resistance of the shell, decreases initial drug burst, 
and prolongs the release time in biologically relevant media. It allows preserving the 
active lactone form of the CPT in the course of the nanocapsules’ incubation with cancer
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cell. As a result, the activity of CPT encased into LbL nanocapsules towards CRL2303 
glioblastoma cell is improved three-fold. By changing the architecture of the PE 
assembly, the CPT loading capacity was increased to ~ 78%. In the next chapter, a step 
forward in applying LbL assembly for delivery of more nanomicelle core of PTX is 
described.
CHAPTER 5
APPLICATION OF LAYER-BY-LAYER ASSEMBLY FOR 
NANOMICELLAR CARRIER OF LOW SOLUBLE ANTICANCER 
DRUG WITH IMPROVED COLLOIDAL STABILITY AND
BIOAVAILIBILITY
5.1 Introduction
Chapter 4 describes the application of the developed washless LbL assembly for 
encapsulation of more poorly soluble drug PTX loaded in nanomicelle cores. Three step 
approaches were tried to reduce the hydrodynamic size along with colloidal stability of 
PTX LbL formulation: 1) drug encapsulation in the nanomicelle core; 2) assembly of PEs 
on top of it; and 3) conjugation of a PEG trail on the outermost surface of the PTX 
formulation to prevent any serum protein adhesion. In a previous work by Shutava et al.
[11], a nano-colloidal core of PTX was formulated along with dioctyl sodium 
sulfosuccinate (AOT), an anionic surfactant, poly vinyl pyrrolidone (PVP), a non-ionic 
surfactant, and Tween 80, with the drug being in its meso-crystalline form. It was further 
coated LbL assembly of cationic PEs, Poly L-lysine, PLB16-5, PLB 16-20 and Heparin, 
and extra PEGylated with mPEG-SVA. The LbL architecture was optimized, and it was 
found that PLB 16-5/HEP assembly obtained a colloidal stability of ~200 nm for 7-8 days. 
A maximum of 7.5 bilayers (PLB 16-5/Heparin) was assembled. Such a previous study 
helped to select the cationic and anionic PEs which could be used for effective 100-200
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nm scaled formulations. The QCM studies indicated that higher concentration (0.5 
mg/mL) and longer tails of PEG grafted to poly-L-lysine, significantly resisted serum 
protein (FBS) adsorption. These concepts from Shutava et al. [11] and Parekh et al. [12] 
were applied for further improvement of the delivery system for PTX. The main aim was 
to have smaller particle size of -100 nm, a better colloidal stability of more than 14 days, 
high drug loading capacity between 30-50%, ability to preserve the anticancer activity of 
PTX, thus showing a significant anti-tumor effect, if possible an improved circulation 
time of > 4 h, and better bioavailability of drug in a mice model. In addition to these 
objectives, an attempt was also made to optimize the shell structure of PTX nanocolloidal 
formulation, a previous work in Shutava et al. [11], by using different anionic 
polyelectrolytes for reduced immune response and longer circulation.
S.2 Materials and Methods
5.2.1 Materials
PTX was obtained from L.C. Laboratories, tocopherol polyethylene glycol 1000 
succinate (TPGS), dioctyl sulfosuccinate sodium salt (AOT) from Sigma Aldrich. The 
other polyelectrolytes and poly ethylene glycol molecule were the same as mentioned in 
Chapter 4.
5.2.2 Core nanomicelle formation
AOT (Dioctyl sulfosuccinate sodium; an anionic surfactant), 3.8 mg/mL and 
TPGS (D -a-Tocopherol polyethylene glycol (1 kDa) succinate, anon-ionic surfactant),
1.5 mg/mL, were taken in different ratios and dissolved in CHCI3. This mixture was then 
dried under N2 purge to form a thin film. The film was resuspended in 2.5 mL PBS pH
7.2 and sonicated for 2-3 min. Then the PTX stock solution in acetone was added drop-
67
by-drop with continuous sonication to form a final PTX concentration of 1.25 mg/mL. 
The sonication was continued for 15 min, until the mixture became transparent. The zeta 
potential was measured, which was expected to be negative. Further in the article, this 
PTX nanocore is referred to as AGCX.
5.2.3 LbL assembly on nano-core
After the nano-core is formed, 2.5 bilayers of alternating PLB 16-5 and HEP were 
assembled (final mass being -1.31 to 1.03 mg/layer/mg of PTX). For the initial bilayer, 
each layer has to be sonicated for a longer time, i.e. 5 min, than the rest of the layers, 
which was for 2 min. After 1 hr of ageing, the sample was washed at 14,000 rpm 
(Eppendorf 5804R centrifuge) for 10 min. The supernatant obtained was the final sample 
of interest, indicated as AGCX-LbL. The pellet was resuspended in the same volume of 
PBS, pH 7.2, i.e. 2.5 mL and re-dispersed under continuous sonication. For extra 
PEGylation, dry powder of mPEG5kDa-SVA (Laysan Bio Inc.) was added directly after 
the last PE layer of heparin i.e. (PLB 16-5/HEP) 3.0 bilayers. It was followed by 
sonication to have a final PEG concentration of 20 mg/mL.
After overnight ageing, the dispersion was washed similarly at 14000 rpm 
(Eppendorf 5804R centrifuge) for 10 min. The supernatant collected was the final extra 
PEGylated sample, i.e. AGCX-LbL-PEG. The pellet was re-dispersed in the same way as 
before. For both AGCX-LbL and AGCX-LbL-PEG samples, the dispersion after pellet 
re-suspension was used for measuring the % drug loading capacity. Procedure and 
calculations of it are described in Section 5.2.4.1. Various ratios of both surfactants and 
PTX drug were tried during optimization of formulation, details of which are mentioned 
in APPENDIX B, Table B.l-1. The stability and zeta potential values of these nano­
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micelle cores are shown in Figure 5-4. The final concentrations of each reagent and PTX 
drug for the optimized formulation is listed in Table 5-1. The above formulation process 
was also tried with another anticancer drug, Lapatinib, which has more solubility than 
PTX. Due to the difficulty in determining the amount of Lapatinib, the formulation was 
made for PTX. The chemical stability of Lapatinib was analyzed by HPLC (Agilent 
1100), in Figure B.2-2 and Figure B.2-3. For more details, see APPENDIX B, Section 
B.2.
Table 5-1: Composition of AGCX formulation: LbL coating on PTX loaded 
nanomicelle.
















AGCX 3.765 1.51 1.255 3 1.203 0.401 4.203 1.3
* NI- Non Ionic, I- Ionic; **PE- Polyelectrolyte (HEP or PLB 16-5)
5.2.4 Percentage calculations
5.2.4.1 Percentage drug encapsulation
Since the drug was encapsulated in a nano-micelle, it was retrieved in the 
supernatant after the washing step. The pellet was re-dispersed in the same volume of 
PBS pH 7.2. A small aliquot (20 pL) of this dispersion was diluted 100 times in acetyl 
nitrile. It was then washed at 14,000 rpm (Eppendorf 5804R centrifuge) for 10 min. The 
% drug encapsulated was calculated using the following formula:
% Drug gncapsidatlon =  Eq. 5-1Initial «mc*of PTX used f c r  ftrm u la tion  ’
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The UV absorbance of the supernatant was measured at 227 nm (e = 28845.93 M" 
^ m '1 or 33.781 mg'Icm‘1mL) in acetyl nitrile.
5.2.4.2 Estimation of amount of TPGS. %
It was also important to analyze the percentage of other reagents present in the 
final formulation of AGCX-LbL and AGCX-LbL-PEG. For TPGS analysis, the pellet 
dispersion after the washing step of LbL or extra PEGylation was re-dispersed in acetyl 
nitrile, 101 dilutions, and washed again. This supernatant was analyzed at 273 nm for its 
absorbance. Similarly, before washing, AGCX-LbL was analyzed at 273 nm. The % of 
TPGS present in the formulation was calculated by the following formula:
TPGS (A b so rb an ce  2 7 3 n m ),%  =
({H m  wasit*d AGCX LbL -  D ispm std p tl ltt  AGCX LbL or AGCX LbL PEG)\
1 _ f, IX 100 %• 5—2x Non washmd AGCX LbL /
5.2.5 SEM and crvo-TEM sample preparation
The drug dispersion was dropped on a clean silicon wafer, and was dried at room 
temperature. The silicon wafer and the dried sample were then coated with 20 nm of gold 
and then examined with the SEM. Cryo TEM samples were prepared and vitrified by 
using Vitrobot manufactured by FEI and the samples were run on cryo TEM, FEI Tecnai 
G2 F30 Twin. Cryo TEM was done to preserve the soft core of nanomicelles during 
electron microscope imaging.
5.2.6 Colloidal stability in FBS
Colloidal stability in FBS was estimated for the following samples individually:
1) AGCX nanocore, 2) LbL coated nanocore as AGCX(PLB/HEP)2.5, and 3) Extra 
PEGylated nanocore as AGCX(PLB/HEP)2.5_mPEG-SVA. 30 pL of corresponding PTX
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sample was added in 2 mL of FBS (pH7.4) and mixed well. It was then immersed in a 
water bath at 37.5° C. The study was done for a total of 48 h, under continuous stirring at 
1000 rpm (Eppendorf 5804R centrifuge). At different time intervals, samples were 
analyzed for the hydrodynamic size and zeta potential.
5.2.7 In vitro release study Tween 80
Release studies for extra PEGylated AGCX samples were done in PBS at pH 7.4 
with 2% w/v Tween 80 at 37.5° C. Different volumes of PTX dispersion were taken from 
the stock and added to 30 mL of preheated PBS mixture. The release medium was kept 
under continuous stirring. The PTX concentrations studied were 24, 12 and 3 pg/mL. At 
release time periods of 0.5, 1 ,3 ,6 ,12 , and 24 hrs, 200 pL aliquots of release medium 
were extracted and replaced with the same volume of PBS, pH 7.4 with 2% Tween 80.
5.2.8 Percentage drug released calculation
It was necessary to calculate the amount of free drug released in the release 
medium to analyze the release of the drug at individual time points. For the UV study, out 
of 200 pL of released medium collected at different time points, aliquots of 20 pL were 
diluted in 2 mL of Acetyl Nitrile and were centrifuged at 14,000 rpm (Eppendorf 5804R 
centrifuge) for 10 min. The supernatant was then analyzed in UV vis at 270 nm 
wavelengths, with extinction coefficient being 482817.8 M 'cm '1 or 565.42 mL mg"1 cm'1. 
The solubility of PTX in the water is less than 12 pM or 10 pg/mL [109].
5.2.9 Cytotoxicity studies
4T1 breast cancer cells purchased from The American Type Culture Collection 
(ATCC; Manassas, VA) were grown and maintained in RPMI, pH 7.4, supplemented 
with 10% (v/v) FBS and 1% of penicillin/streptomycin stock solution in a humidified, 5%
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(v/v) C02 atmosphere at 37° C. The cytotoxicity studies were observed in 4T1 breast 
cancer cell lines, 4000 cells/well. The control used was Cremaphor-EL vehicle. The cells 
were treated with: 1) free PTX, 2) LbL coated AGCX nanocores, and 3) extra PEGylated 
AGCX nanocores. The concentration range used was from 16 ng/mL to 1 pg/mL. Cell 
titer blue cell viability assay was performed for cell viability studies.
5.2.10 In vivo mice studies
The in vivo mouse and cell culture studies were done in Northeastern University, 
Department of pharmaceutical sciences, at Dr. Torchilin’s laboratory in Boston, MA.
5.2.10.1 Mouse model
4T1 cells (2 x 106) were inoculated subcutaneously in the left flank of female 
Balb/c mice. PTX drug formulation were injected intraperitoneally (i.p.) to the mice 
when the tumor volumes were about 200 mm3. LbL samples and extra PEGylated 
samples of PTX (AGCX core) were injected, each to 8 mice, with 4 injections on 
alternated days. Each injection was of 0.5 mg/mL, 0.5 mL in PBS solvent, pH 7.4. 
Simultaneously, 2 mice were injected with 0.5 mL of the same concentration of heparin 
PE present in PTX sample i.e. 0.9375 mg/mg of PTX. For animal studies only, instead of
2.5 bilayers, 1.5 bilayers of PLB 16-5/HEP were assembled as an LbL coating. Fewer 
bilayers were used to minimize the process steps and reduce the use of PEs by 33 wt. %. 
Tumor volumes, tumor weight, and body weight were monitored every alternate day.
Animals that completed the entire study successfully were only included in the 
analysis. Mice were constantly monitored and allowed for free access to food and water 
(following the animal care protocol no. 13-1242 R. approved by Northeastern University 
Institutional Animal Care and Use Committee, in accordance with the “Principles of
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laboratory animal care,” NIH publication no. 85-23, revised in 1985). The tumor volume 
was calculated using the formula V = 0.5 (length * width2) by measuring the dimensions 
of the tumor at regular time intervals. Statistical analysis included a one-way ANOVA 
followed by Tukey’s post-hoc test and Kruskal-Wall test.
5.2.10.2 Tumor growth inhibition
The treatments of tumor-bearing mice started 7 days after 4T1 cell inoculation.
All 4 doses were of 12.5 mg PTX/kg every 2 days administered via tail vein. Each 
treatment group consisted of 5-6 mice. Tumor volume was estimated as V = 0.5 (length x 
width2) every 2 days from the beginning of treatments. At +8 days after the first injection, 
mice were sacrificed, and tumors were excised and weighed. The control group was 
treated with PBS, pH 7.4. The injections were of Taxol (free PTX drug), AGCX-LbL, 
and AGCX-LbL-PEG.
5.3 Results and Discussion
5.3.1 Morphological characterization of nanomiceller LbL formulation
The AGCX-LbL and AGCX-LbL-PEG samples are shown after the washing steps 
in Figure 5-1. Both of the dispersions seem to be translucent. AGCX-LbL sample seems 
to be more clear than extraPEGylated ones.
Figure 5-1: AGCX-LbL and AGCX-LbL-PEG samples after washing steps.
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The SEM images confirmed that after LbL assembly, the supernatant had the 
nano-micelles. They had a bit of irregular border due to the non-uniform LbL coating, as 
seen in Figure 5-2(a). It had an average hydrodynamic diameter of 127±5 nm after 7 
days. While the resuspended pellet after washing exhibited the nano-crystalline core as 
seen in Figure 5-2(b). As seen in Figure 5-2(c) and (d), the extra PEGylation had made 
the surface look more uniform and spherical.
Figure 5-2: SEM of AGCX(PLB/HEP)2.5bilayer -  (a) Supernatant; (b) pellet re­
dispersed; (c) and (d) extra-PEGylated (7th day). Done at Tulane University, New 
Orleans, LA.
Since the nanocores were confirmed to be nanomicelles, cryo-TEM was used to 
confirm the exact shape in cryo state. Figure 5-3(a, b) shows that the border of the 
nanocores were bit irregular. After LbL assembly, it smoothes out (Figure 5-3c).
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Furthermore, extra PEGylation on top of LbL coating seems to fill the gaps between 
irregular PE/s LbL assemblies, thus making the nanocores more uniformly spherical, as 
seen in Figure 5-3d. The thick lines seen in the TEM images are the channels of the 
sample grid.
Figure 5-3: Cryo TEM of AGCX: (a) and (b) nanomicelle core; (c) LbL coated; (d) extra 
PEGylated on LbL assembly. Done at Tulane University, New Orleans, LA.
5.3.2 Optimization of PTX a nano-micellar LbL formulation
Various ratios of TPGS, AOT and PTX were analyzed in the formulation for 
optimization. Further increase in the amount of surfactant is required for higher drug 
encapsulation. Best colloidal stability was observed for low TPGS/AOT ratio of 0.401 
and a low total surfactant (ionic + non-ionic) to PTX ratio of 4.203. See Table B.l-1 in
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APPENDIX B. An unexpected decrease in particle size was observed with an increase in 
the initial PTX concentration (Figure 5-4).
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Figure 5-4: The upper graph -  composition a hydrodynamic size of the nano-micelle 
core, %PTX encapsulation of the final formulation after LbL assembly; the lower graph -  
the zeta potential of surface just after nano-micelle core formation.
As the concentration of the PTX drug was increased, the approximate amount of 
polyelectrolyte required for a PE layer deposition was almost the same. This trend was 
especially seen along the samples AGCX9 to AGCX13. The amount of PE per PTX for 
one layer assembly decreases simultaneously from 8.79 to 2.17 mg/ [PTX]. See Figure 
5-4. When the zeta potential of nano-micelle core was sufficiently negative, -20< C< -15 
mV, smaller particle size was achieved after 2.5 bilayers of PEs assembly. Further layer 
deposition lead to insufficient charge reversal. It indicated the destabilization of the LbL 
assembly. This destabilization could be caused by aggregation of counter free PEs 
floating in the dispersion mixture.
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The negative zeta potential value of-38±2 mV, just after the core AGCX 
formation, was due to dominance of excess of sulfate ion heads of AOT pointing out of 
the micelle core (Figure 5-5a). Such a high negative potential will support further LbL 
assembly of PEs. The amount of PEs required for the first layer, i.e. PLB 16-5 is in the 
high 60 mg/mL, 70 pL in 2.5 mL of dispersion or final concentration of 1.31 mg/mL. The 
amount of PEs for other layers is approximately 1.03 mg/mL. The amount of PEs 
required for nanomicelle coating is higher than that in the previous formulation of CPT 
(CHAPTER 4). The larger amount can be explained on the basis that the hydrodynamic 
size is smaller (approx 100 nm) than that of CPT (150 nm). The % PTX encapsulation 
calculated using Eq. 5-1, and it was approximately 60-70% for both AGCX-LbL and 
AGCX-LbL-PEG. The % TPGS calculated using Eq. 5-2 was 70-80% (Table 5-2). The 
UV absorbance graph for the sample can be seen in Figure B.l-1 in APPENDIX B.
Table 5-2: Details of samples: Zeta potential, Particle size, % PTX concentration, % 
TPGS concentration.
Sample % PTX Encapsulation %TPGS
AGCX LbL mPEG 62 74
AGCX LbL 66 73
(a)
1 2 3 4 5 6  14 30
Days
E3AGCX12(P/H)2.5 S  AGCX12(P/H)2.5_PEG
Figure 5-5: (a) Zeta potential of AGCX during formulation process and (b) 
Hydrodynamic diameter of AGCX 12 after LbL coating and extra PEGylation in PBS pH 
7.4. Colloidal stability study of 30 days.
5.3.3 Colloidal stability of LbL coated nanomicellar core
The colloidal stability of extra PEGylated sample in PBS at pH 7.4 was good for 
AGCX core, with a hydrodynamic size of 97±2 nm after a 14-day study, while after 30 
days it was still 105 nm. See Figure 5-5b. Colloidal stability in FBS also contained 
studies of AGCX-LbL and AGCX-LbL-PEG and the AGCX core. Along with particle
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size distribution for a 48 h stability study, zeta potential was also measured. For all of 
them an exponential increase in hydrodynamic size (Figure 5-6, values for 100% AUC 
are indicated due to bi-phasic distribution) was observed in the following order: AGCX- 
LbL-PEG > AGCX-LbL > AGCX-core, with AGCX-LbL-PEG having max peak at 481 
nm, AGCX-LbL at 1010 nm, and AGCX-core at 1455 nm. As the colloidal stability 
decreases, the zeta potential value also dips more; as for the case of AGCX-LbL 
(AGCX(P/H)2.5), the change in Z.P. value from 0 h to 48 h is ~ 33 mV, and for AGCX- 
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Figure 5-6: Colloidal stability of AGCX low and high PEGylated samples in FBS, pH 
7.4, at 37.5° C. Maximum peak values of hydrodynamic size with % AUC =100 
indicated.
5.3.4 Release study of LbL and PEGylated nanomicelle
As per the release profile of high PEGylated AGCX nanoparticles, all the 
concentrations (0.003 to 0.024 mg/mL) seem to have a similar profile. The highest 
concentration of AGCX NPs have the lowest release. This trend can be explained. As the
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solubility limit of PTX is 0.008 mg/mL, most of the PTX released gets precipitated, thus 
leading to lower % of PTX release. See Figure 5-7. All the release profiles seem to 
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Figure 5-7: Release study of high PEGylated AGCX in PBS with 2% Tween 80, pH 7.4 
at 37.5° C.
5.3.5 Cell culture studies on 4T1 breast cancer cell lines
ICso concentrations strongly decreased for LbL coated and extra PEGylated 
AGCX cores, as compared to free PTX (Taxol). See Table 5-3.
Table 5-3: IC50 of AGCX formulation and its comparison with Free PTX (Taxol), in 
pg/mL and nM.




The values were obtained from the cytotoxicity experiment on 4T1 breast cancer 
cells. LbL coating improved the cytotoxicity -4.5 times having an ICso of 221 nM, while
8 0
that of Taxol was found to be 991 nM. Cytotoxicity improved slightly after extra 
PEGylation with mPEG-SVA on the LbL coating, reducing the IC50 to 153 nM. The IC50 
values are calculated from the cytotoxicity results shown in Figure B.l-2, Appendix B. 
5-3.6 In vivo mice studies
The results in Figure 5-8 are analyzed taking only those mice into consideration, 
which have a tumor volume in the range of 80-200 mm3 at 0 h time of study. The rest 
have been excluded. Instead of standard deviation, standard error has been indicated for 
each data point, where Standard Error = Standard Deviation Nn, and “n” is the number of 
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Figure 5-8: Tumor activity (mm3) study of 8 days: injected with 1) PBS as control; 2) 
Taxol (Free PTX drug), 3) AGCX-LbL, and 4) AGCX-LbL-PEG, on mice injected with 
4T1 breast cancer cells. A study of 8 days. Standard Error (SE) values have been shown 
and n = 6.
The results have been shown for 3 injections, i.e. 6 days. The average tumor 
volume at 0 h was 112-119 mm3. The control mice injected with PBS showed an 
exponential increase in tumor volume at a rate o f -44.6 mm3/day, while for Taxol it was 
-36.1 mm3/day, for AGCX-LbL -25.7 mm3/day and for AGCX-LbL-PEG -11.8
-■ -T a x o l (Fraa PTX d n « ) 
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mm3/day. Until 2 injections the tumor volume remains almost the same for Taxol and 
AGCX-LbL-PEG. After the 3rd injection, tumor volume increased steeply. After the 4th 
injection, some cases of toxicity led to hemorrhaging in the stomach and colon. Earlier 
reports have suggested that the administration of tocopherol acetate or Vitamin E may 
increase the risk of hemorrhaging [110], but still the correct explanation and confirmation 
of the data has not been found. A specific reason for the toxicity was not determined in 
the mentioned mice experiments due to shortage of mice for further experiments.
5.4 Conclusion
A significant improvement in the LbL process for low soluble drug encapsulation 
has been made. The number of process steps were reduced by: 1) coating with only 2.5 
bilayers of PE to attain such a high colloidally stable formulation, 2) high PEGylated 
samples had no washing step just after the LbL assembly, as it was the step for CPT [12] 
in CHAPTER 4 and for PTX in Shutava etal. [11]. A significantly improved colloidally 
stable formulation for LbL coated samples of 121 nm and a highly PEGylated sample of 
105 nm were attained even after 30 days in PBS pH 7.4. It had a high drug encapsulation 
capacity of 30-40% and ~6.5 times higher cytotoxicity against 4T1 breast cancer cells, 
with an IC50 of 153 nM. Injection of such PTX nano formulation to mice was safe 
(survival mice rate was ca. 85%) and showed an improved antitumor effect in mice. 
Toxicity was found in some mice, the reason for which can be studied in the future to 
improve the formulation.
In the next chapter, the techniques of washless LbL assembly from CHAPTER 4 
and assembling less layers of LbL with fewer washing steps from CHAPTER 5 are
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combined, to improve the circulation time significantly, and bioavailability of nano lipid 
carrier (NLC) for anticancer drug DOX.
CHAPTER 6
ENHANCED PHARMACOKINETICS AND TUMOR GROWTH 
INHIBITION USING A NANOSTRUCTURED LIPID CARRIER 
LOADED WITH DOXORUBICIN AND MODIFIED IN A LAYER- 
BY-LAYER POLYELECTROLYTE FORMULATION
In this chapter, a step further has been taken in the application of washless 
technique of LbL assembly for improving the colloidal stability by narrowing down the 
particle size distribution of lipid nanoparticles, such as solid nanoparticles (SLN) and 
nanostructured lipid carriers (NLC). The study also adopts the concept of using fewer PE 
layers for LbL coating, making the process shorter, simpler, and thus cheaper. Such an 
approach is expected to increase the circulation time in the blood, lower accumulation in 
the liver, and increase accumulation in tumors while improving the tumor growth 
inhibition effect.
This work was done in collaboration with Center for Pharmaceutical 
Biotechnology and Nanomedicine, Northeastern University, Boston at Dr. Torchilin’s 
lab. The NLC-DOX core were developed, and the cytotoxicity and in vivo mice 
experiments were done at Dr. Torchilin’s lab. Furthermore, the rest of the stabilization 
process by LbL assembly process was done at Institute for Micromanufacturing, 
Louisiana Tech University at Dr. Lvov’s lab. A manuscript from this work has been 
submitted at International Journal of Pharmaceutics and is under review [25].
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6.1 Introduction
Many reports have described the advantages of lipid nanoparticles such as solid 
lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC). These nanoparticles 
have been widely described as promising drug delivery systems for the treatment of 
cancer. Previously the co-encapsulation of DOX and docosahexaenoic acid (DHA) in 
SLN and NLC for the enhancement of drug antitumor effects has been proposed [13,
111]. The SLN co-loaded with DOX and DHA were more cytotoxic than free drugs 
against the human lung A549 cancer cell line in monolayer cultures [111]. The developed 
NLC co-loaded with DOX and DHA were more cytotoxic against the sensitive MCF-7 
breast cancer cell line and even more potent against the drug resistant MCF-7/Adr cell 
line than the free drugs. The higher cytotoxicity against the MCF-7/Adr was also verified 
in a cultured spheroid model. It was suggested that the NLC overcame drug resistance 
due to a bypass of the glycoprotein P bomb efflux effect [13, 112].
To further improve the anticancer effect of the NLC co-loaded with DOX and 
DHA and to improve the colloidal stability by narrowing the particle size distribution, the 
surface modification of the nanoparticles with an LbL technique involving an alternate 
adsorption of polycation and polyanion on a charged substrate was considered [11]. The 
LbL film promotes a controlled release of drug by controlling the diffusion of drug from 
the solid core to the external medium [12]. NLC loaded with DOX is a solid lipid core 
with a sufficient surface negative charge to support a LbL architecture [13,113]. LbL 
polymeric films are typically uniform and sufficiently adherent to charged surfaces [11,
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Recently, a washless technique of polyelectrolyte adsorption has been developed 
based on the addition of each shell layer in a precise amount, determined by titration, that 
leads to almost complete charge reversals (+/-15 mV). This method avoids intermediate 
washing after each layering and significantly reduces the process time. Additionally, the 
reduction of total poly electrolytes used lowers the cost of the whole process [11,12]. Its 
recent application in encapsulation of drugs with low solubility such as PTX [11] and 
CPT [11,12] improved their colloidal stability and cytotoxicity.
For this study, the surface of NLC co-loaded with DOX and DHA has been 
modified by the LbL technique to evaluate drug release, characteristics of the 
nanoparticles, cytotoxicity against human and murine cancer cell lines, and in vivo 
biodistribution and tumor growth inhibition.
6.2 Materials and Methods
6.2.1 Materials
DOX hydrochloride was purchased from LC Laboratories (Woburn, MA). 
triethanolamine (TEA), oleic acid (OA), polyvinyl pyrrolidone, 10 kDa (PVP) and the 
negative polyelectrolyte (PE), heparin sulfate (HEP) were purchased from Sigma- 
Aldrich. Positive PE as poly-L-lysine 16 kDa and block co-polymer-polyethylene glycol, 
5 kDa (PLB16-5) were from Alamanda Polymers, Inc. Additional PEGylation was done 
with methoxy polyethylene glycol 5 kDa, succinimidyl valeric acid (mPEG5kDa-SVA) 
from Laysan Bio, Inc. Glyceryl behenate (Compritol 888 ATO®) was kindly provided by 
Gattefosse (Rhone-Alpes, France). Monooleate of sorbitan ethoxylated (Super refinedTM 
polysorbate 80; Tween TM 80) and docosahexaenoic acid (DHA) as triglyceride 
(Incromega™ DHA 500TG) were kindly provided by Croda, Inc. Dulbecco's modified
eagle medium (DMEM), antibiotic stock solution (10,0001.U. of penicillin + 10,000 
pg/mL of streptomycin) and 0.25% Trypsin-EDTA were purchased from CellGro. Heat 
inactivated FBS was purchased from Atlanta Biologicals. Centrifugation devices used 
were Amicon® Ultra - 4 100 k, Millipore. The Cell Titer Blue assay kit and CytoTox 
96® Non-Radioactive Cytotoxicity Assay were purchased from Promega. All other 
chemicals were of analytical grade.
6.2.2 Preparation of Nanostructured Lipid Carrier fNLO of Doxorubicin
The nanostructured lipid carrier (NLC) loaded with DOX was prepared at 
Northeastern University. The preparation and the composition of the formulations were 
previously described [13]. A batch was of 5 ml of formulation. The oily phase (OP) was 
prepared with 100 mg of Tween 80, 10 mg of oleic acid, 5 mg of DOX, 6 mg of 
triethanolamine and 150 mg of matrix lipid composed of 110 mg of Compritol and 40 mg 
of DHA (0.4% w/v). This formulation was referred to as “NLC-DOX”. The aqueous 
phase (AP) was composed of purified water. After preparation, the pH was adjusted to 
7.0-7.5 and a final volume of 5 mL. First, the OP and the AP were heated separately to 
80° C. After OP melting, the AP was added drop-wise into the OP and homogenized 
using a glass rod for 1 min. This emulsion was immediately subjected to intense probe 
sonication (8 Watts) for 5 minutes, using a high intensity ultrasonic processor (Fisher F60 
Sonic Dismembrator Fisher F-6; Fisher Scientific, Pittsburgh, PA). The pH was adjusted 
to 7.0 with 0.1 M HC1 and 0.1 M NaOH. The formulation was stored at 4° C, protected 
from light in a nitrogen atmosphere. The NLC-DOX cores were formulated at 
Northeastern University, Dept, of Pharmaceutical Science.
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6.2.3 Laver-bv-Laver assembly
NLC-DOX (3 mL, with approx. 1 mg/mL of DOX encapsulated) was added to a 
small glass bottle. To form NLC-DOX-PVP (NDP), approximately 4 mg of PVP was 
added with simultaneous sonication, for a final concentration of 1.31 mg/mL. The 
sonication was continued for an additional 10 minutes to stabilize these NLC cores. Zeta 
potential measurements confirmed the negative charge (-15 to -20 mV) necessary for a 
proper LbL poly electrolyte (PE) assembly. The first layer assembled was with a positive 
PE (-4.8 mg of PLB16-5) added to the NDP mixture under continuous sonication. 
Similarly, a total of 2.5 bi-layers of alternating HEP/ PLB16-5 were assembled by adding 
lower amounts of each PE, -1.9 mg, with the final outermost layer of HEP. Each 
assembled layer was sonicated for 2 to 3 min. The complete process was conducted in a 
deionized (DI) water medium, maintained at pH 7.4. For an extra-PEGylated sample, a 
dry powder of mPEG5kDa-SVA was added directly to the above LbL formulation with 
PLB16-5 as the outermost layer. Sonication was done in cold water at 10° C to ensure a 
temperature lower than the melting point of OP, i.e. 80° C [13]. The succinimidyl 
valerate (SVA) group in mPEG5kDa-SVA was an N-hydroxyl succinimidyl ester group 
(-NHS ester) conjugated to methoxy PEG. It readily conjugates mPEG group with excess 
-NH2 groups on a surface side by releasing free NHS in the medium [114]. The final 
concentration of mPEG5kDa-SVA added to the dispersion was 20 mg/mL. The mixture 
was sonicated for 5 min and then kept overnight for ageing [12]. The mixture was spun at
14,000 rpm (Eppendorf 5804R centrifuge) for 10 min, and the supernatant was collected; 
the pellet was discarded. The NDP LbL formulation has a lipid-based core. Thus, it was 
suspended in the supernatant. This supernatant, NDP(PLB16-5/HEP)2.5/mPEG was
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finally termed “NLC-DOX-LBL-PEG”. For just the LBL sample with no extra 
PEGylation, 3 bilayers of (PLB 16-5/HEP) were assembled, i.e. HEP as the outermost 
layer was similarly washed. The obtained supernatant NDP(PLB16-5/HEP)3.0 was 
termed “NLC-DOX-LBL”. Zeta potential was measured after each additional layer 
deposition to confirm complete charge reversal between -15 and +15 mV.
The formulations were further purified prior to the in vitro and in vivo studies to 
remove the unloaded DOX and the unattached polymers by ultrafiltration using 
Amicon® Ultra-4,100 ldDa MWCO centrifugal filter devices (Sigma-Aldrich). About 2 
ml of formulations were added to the devices and centrifugation performed for 15 min at
5,000 rpm (Eppendorf 5804R centrifuge) and 4° C. The retantate was resuspended in a 
5% glucose solution.
6.2.4 Characterization of formulation
The mean particle diameter and zeta potential were measured by dynamic light 
scattering (DLS) and electrophoretic mobility, respectively, using the Zeta PLUS particle 
size analyzer (Brookhaven Instruments; Holtsville, NY). All measurements were 
performed in triplicate.
The encapsulation efficiency (EE) and drug loading (DL) of DOX in NLC were 
determined by an ultrafiltration method using Amicon® Ultra-0.5 mL, 100 kDa MWCO 
centrifugal devices (Sigma-Aldrich) with the membrane passivated with a 5% aqueous 
solution of Tween™ 20 to eliminate DOX binding as previously described [111]. The EE 
and DL were calculated using the following equations:
EE (%) = ( C t  -  C a p ) /C t  x l 00. Eq. 6-1
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Where C t  = total DOX concentration in NLC, C ap = DOX concentration in aqueous 
phase (non-encapsulated).
DL ( m g / g )  -  W dl/ W np. Eq. 6-2
Here W dl = mg of drug loaded in nano-particles and W np -  grams of nanoparticles 
(lipids).
Briefly, the C t , C ap and W dl were evaluated as follows. The C t was determined 
by dissolving an aliquot o f200 pL the NLC dispersion in 5 mL of a mixture of 
tetrahydrofuran (THF)/methanol (MeOH) 4:6 v/v, centrifugation for 10 min at 2,400 x g 
and analysis of the supernatant by spectrophotometry at 480 nm (UV-mini 1240; 
Shimadzu, Japan). The C ap was evaluated from an aliquot of the aqueous phase 
separated from the NLC dispersion by ultrafiltration (10 min at 2,400 g), dilution with 
THF/ MeOH and analysis by UV-visible. The WDL was derived using the calculated EE 
x mg total of DOX added.
6.2.5 Colloidal stability study
The colloidal stability was checked by diluting the dispersion 100 times in PBS, 
pH 7.4. The hydrodynamic size was measured by particle size analysis on the 1st, 7th, and
14th storage day for both LbL and PEGylated samples. The average values were from 20
readings taken on each sample to confirm the particle size distribution (PSD).
6.2.6 SEM sample preparation
The dispersion was diluted 10 times in distilled water, pH 7. A drop of each 
sample was allowed to dry on a clean silicon wafer at room temperature. Before SEM 
imaging, a 12 nm thickness of gold was sputtered at 40 mA run for 30 sec. The FE-SEM 
was observed at 1.5 kV to prevent burning of polymer coated samples.
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6.2.7 Transmission electron microscopy
Nanoparticles were negatively stained with 1.5% uranyl acetate, and images were 
taken using a JEOL TEM-1010 transmission electron microscope (JEOL USA, Inc., 
Peabody, MA) operating at an acceleration voltage of 80 kV. The images were captured 
at a 20,000x magnification.
6.2.8 Release of doxorubicin from NLC
The release study was performed at Northeastern University by analysis of 
dialysis in PBS, pH 7.4 [13]. Cellulose ester membrane dialysis tubing with a cutoff size 
of 100 KDa (Spectrum Laboratories; Rancho Dominguez, CA) were filled with 3 mL of 
formulations loaded with DOX or DOX aqueous solution (~0.5 mg/mL) diluted in the 
buffer 1:2, sealed and incubated with 50 ml of the media for up to 24 h at 37° C with 
continuous 250 rpm (Eppendorf 5804R centrifuge). At various time points, 1 mL of 
solution was withdrawn and replaced with an equal volume of the media. The DOX 
concentrations were measured by spectrofluorimetrically with a Synergy HT Multi-Mode 
Microplate Reader (Biotek; Winnooski, VT) at 485/590nm ex/em wavelengths. The 
values were plotted as percentage of cumulative drug release.
6.2.9 In vivo studies
Cells, 4T1, purchased from The American Type Culture Collection (ATCC; 
Manassas, VA) were grown and maintained in RPMI, pH 7.4, supplemented with 10% 
(v/v) FBS and 1% of penicillin/streptomycin stock solution in a humidified 5% (v/v) C02 
atmosphere at 37° C.
For subcutaneous injection over the left flank region, a 100 pL suspension of 
2x 106 4T1 cells in RPMI serum free were injected in 6-8 week old BALB/c mice for
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biodistribution and tumor growth inhibition studies. The time for the initial detection of a 
tumor was about 7 days when tumors were about 100-150 mm3. Mice were regularly 
monitored and allowed for free access to food and water following an animal care 
protocol (13-1242 R) approved by the Northeastern University Institutional Animal Care 
and Use Committee in accordance with the “Principles of laboratory animal care”, NIH 
publication no. 85-23, revised in 1985). Tumor volumes were calculated using the 
formula V = 0.5 (length x width2) by caliper measurements of tumors at regular time 
intervals.
6.2.10 Biodistribution study
Groups of 4-5 animals bearing 4T1 tumors were injected on day +7 with a single 
dose equivalent of 5 mg/mL of DOX. The treatments were as follows: (1) Free DOX; (2) 
NLC-DOX; (3) NLC-DOX-LBL, and (4) NLC-DOX-LBL-PEG via the lateral tail vein. 
At 0.5, 1,2, and 4 h post-injection, blood was collected from anesthetized mice by 
cardiac puncture into a heparinized (1 U) tube. The blood was centrifuged at 1000 g for 
10 min at 4° C followed by collection of the upper plasma layer and storage at -80° C 
until use. Liver and tumors were harvested for DOX analysis. The amount of the DOX 
was quantified as previously described by Wang et al., 2014 [115]. Briefly, weighed 
tissue homogenates of 10% (w/v) or 25% plasma (200 pL) were added to a mixture of 
100 pL of 10% (v/v) Triton X-100,200 pL of water, and 1.5 mL of acidified isopropanol 
(0.75 N). Following the extraction of DOX overnight at -20° C, samples were warmed to 
room temperature, vortexed for 5 min, centrifuged at 15,000 g for 20 min and stored at 
80° C until analysis. DOX was quantified fluorometrically (ex/em 470/590 nm). Standard 
curves were prepared using tissues or plasma of mice not treated with DOX.
92
6.2.11 Tumor growth inhibition
The treatments of tumor-bearing mice started 7 days after 4T1 cell inoculation. 
The first two doses were of 2.5 mg DOX/kg every 2 days and then 3 doses of 1.25 mg 
DOX/kg every 2 days administered via tail vein. Each treatment group consisted of 5-6 
mice. Tumor volume was estimated as V = 0.5 (length * width2) every 2 days from the 
beginning of treatments. At +12 days after the first injection, mice were sacrificed, and 
tumors were excised and weighed. The control group was treated with PBS, pH 7.4.
6.3 Results and Discussion
6.3.1 Laver-bv-Laver coated NLC characterization
Figure 6-1 and Table 6-1 show the hydrodynamic sizes and zeta potential of 
nanoparticles with each layer addition. At the first polymer addition, the average size 
increased from 89 nm to 127 nm, and then remained unchanged. The final average size 
for NLC-DOX-LBL was about 138 nm, and for NLC-DOX-LBL-PEG it was 128 nm. 
These samples showed a particle size distribution with a single sharp peak and a low 
polydispersity.














NLC-DOX -40 ± 2 89 + 3 0.291 63(100%),149(80%)
NLC-DOX-LBL -14 + 2 138 + 2 0.092 115(100%)
NLC-DOX-LBL-mPEG 5 + 3 128+1 0.098 129(100%)
Figure 6-2 shows the SEM and TEM images. Both NLC-DOX-LBL and NLC- 
DOX-LBL-PEG samples are irregularly shaped with an average diameter of 150 nm and 
100 nm, respectively. The extra-PEGylated NLC were more uniformly spherical, smaller 
in size and had less standard deviation. The larger, more irregular particles represent 
agglomerates of free, oppositely charged polyelectrolytes. The bright white halos seen in 
the SEM images around most structures represent an edge effect caused by a generation 
of secondary electrons from the curved circumferences of spherical structures [116]. The 
sizes appear to differ between Figure 6-1 and Figure 6-2. The measurements shown in 
Figure 6-1 were taken immediately after the preparation, while the SEM images reported 
in Figure 6-2 were taken 7 days after sample preparation.
The zeta potential of the NLC-DOX lipid core was highly negative, i.e. ~ -40 mV 
(Table 6-1). For this reason, the initial amount of PE (PLB16-5) required to reverse 
surface charge (4.8 mg) was high. For subsequent layers, the amount of HEP or PLB16-5 
needed was lower, (2.4 mg) for complete charge reversal. After each LbL sample was 
washed, surface charge changed slightly due to separation of loosely bound electrolytes. 
The formation of some precipitates was verified. It may have been due to interaction of 
free oppositely charged polymers in the solution. They were removed with the pellet 
during centrifugation steps.
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Figure 6-1: SEM and TEM images: (a) SEM of NLC-DOX-LBL (outermost layer being 
HEP); (b) SEM of NLC-DOX-LBL-PEG (with extra PEGylation), (c) TEM of NLC- 
DOX-LBL, and (d) NLC-DOX-LBL-PEG.
Figure 6-2: Hydrodynamic size and zeta potential along the LbL assembly process and 
extra PEGylation of NLC-DOX. Where, NDP(PLB16-5/HEP)2.5/mPEG is indicated as 
NLC-DOX-LBL-PEG and NDP(PLB16-5/HEP)3.0 as NLC-DOX-LBL.
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The conjugation of mPEG-SVA to amine groups of the NDP (PLB/HEP)2.5 was 
confirmed by a reduction of the zeta potential from high to low positive values, i.e. +5 to 
+2 mV (See Figure 6-1). The colloidal stability of the extra PEGylated sample was better 
compared to the LbL-coated NDP cores (See Figure 6-3).
Figure 6-3: Colloidal stability of NLC-DOX-LBL and extra NLC-DOX-LBL-PEG. The 
maximum peak values of the PSD are indicated as in MSD summary having maximum 
intensity weighted size obtained from Non-negatively constrained Least Squares (NNLS) 
algorithm.
There was a gradual increase in the particle size distribution (PSD) values 
between the 1st and 14th days of the study for both LbL-coated and extra PEGylated NDP 
cores. After 14 days, LbL samples showed a bimodal PSD with a polydispersity of 0.158 
and maximum peaks at 229 nm (100%) and 91 nm (38%). In the extra PEGylated 
samples, the PEG tails outside the LbL assembly improved the colloidal stability due to 
its steric hindrance property [12] as indicated by its narrow unimodal PSD of 178 nm 
with polydispersity of 0.108 after 14 days.
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6.3.2 Drug Release in PBS pH 7.4
The results of the drug release assay performed by dialysis with PBS, pH 7.4 are 
included in Figure 6-4. The released DOX from NLC-DOX was 22 ± 1% in the first 30 
min and increased to 35 ± 2%, 49 ± 2%, and 57 ± 4% at 1 h, 2 h, and 4 h, respectively, 
following which there was no significant release for up to 24 h. In contrast, for NLC- 
DOX-LBL and NLC-DOX-LBL-PEG, the release at 30 min was 10 ± 1% and 9 ± 1%, 
respectively, and increased to 21 ± 1% in 1 h. The release profiles of NLC-DOX-LBL 
and NLC-DOX-LBL-PEG were similar and showed improved capacity to retain the drug 
compared to NLC-DOX (35 ± 2% and 37 ± 0% at 2 h, 41 ± 3% and 47 ± 1% at 4 h, 
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Figure 6-4: DOX release in complete PBS, pH 7.4 by dialysis using a cellulose ester 
membrane (100 Kda MWCO). The released DOX measured in the media was analyzed 
by fluorescence. N = 3; Mean ± SD; *P < 0.05 for the comparison of NLC-DOX-DHA- 
LBL/ NLC-DOX-DHA-LBL-PEG against NLC-DOX and Free DOX. In collaboration 
with Dr. V. Torchilin at Northeastern University, Boston, MA.
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6.3.3 Pharmacokinetic studies
An evaluation of the drug concentration in plasma, liver and tumor for mice 
injected IV with Free DOX, NLC-DOX, NLC-DOX-LBL, and NLC-DOX-LBL-PEG are 
shown in Figure 6-5. The plasma concentrations of free DOX and NLC-DOX were 6.5 ± 
0.9 pg/mL and 8.8 ± 1.1 pg/mL at 30 min; at 2 h, they were 3.8 ± 0.8 pg/mL and 5.3 ±
0.7 pg/mL, and at 4 h, 2.2 ± 0.5 pg/mL, and 4.4 ± 0.5 pg/mL, respectively. NLC-DOX- 
LBL and NLC-DOX-LBL-PEG retained a higher plasma DOX concentration over the 4 h 
period at 10.4 ± 0.6 pg/mL and 12.5 ± 0.5 pg/mL at 30 min, at 8.6 ± 0.6 pg/mL and 11.5 
± 1% at 2 h, and 5.6 ±0.1 pg/mL and 8.7 ± 0.7 pg/mL by 4 h, respectively (Figure 6-5a). 
The formulations with the LbL polymers attached (NLC-DOX-LBL and NLC-DOX- 
LBL-PEG) showed longer longevity in the blood for DOX compared to free drug and the 
plain NLC-DOX formulation. Similar results were seen for solid lipid nanoparticles 
loaded only with DOX and modified with Layer-by-Layer, but using different polymers
[113]. The percent of injected dose in plasma over this time period is consistent with the 
relatively greater retention of DOX for the NLC-DOX-LBL and NLC-DOX-LBL-PEG 
over Free DOX and NLC-DOX (Figure 6-5b).
Figure 6-5 c shows the level of accumulation of DOX in the liver and its decline 
over a 4 h period. It remained highest for the NLC-DOX treatment. NLC-DOX-LBL and 
NLC-DOX-LBL-PEG treatments resulted in lower accumulation than NLC-DOX and 
Free DOX. At 4 h the levels were 0.132 ± 0.01 pg/g , 0.510 ± 0.02 pg/g, 0.177 ± 0,03 
pg/g, and 0.228 ± 0.06 pg/g for Free DOX, NLC-DOX, NLC-DOX-LBL and NLC- 
DOX-LBL-PEG, respectively. The lower accumulation in the liver of LbL formulations 
may have been associated with the generally low level of toxicity observed, while the
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associated higher concentration of DOX in tumors enhanced the antitumor effects. In 
addition to the higher retention of the drug by these formulations, another factor to 
consider is related to the fact that the attached polymers are hydrophilic and may have 
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Figure 6-5: Evaluation of DOX concentration in plasma (a, b), liver (c) and tumor (d) 
after administration of Free DOX, NLC-DOX, NLC-DOX-LBL and NLC-DOX-LBL- 
PEG. The time point for collection of samples were 30 min, 2 h and 4 h. N = 4-5; Mean ± 
SD; *P < 0.05. In collaboration with Dr. V. Torchilin at Northeastern University, Boston, 
MA.
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Figure 6-5d represents the accumulation of DOX formulations in mouse tumors. 
At 30 min after administration, there was no difference of drug concentration in tumors 
among the groups. However, by 2 h, NLC-DOX-LBL-PEG was higher in concentration 
compared to Free DOX. At 4 h, the concentrations in tumors for all NLC-DOX 
treatments was clearly greater than for Free DOX. Additionally, LbL-containing 
formulations were approximately double that of the NLC-DOX levels (p < 0.05). No 
difference was observed between NLC-DOX-LBL and NLC-DOX-LBL-PEG.
6.3.4 Tumor growth inhibition
The evaluation of the effect of treatment on tumor volumes in mice is outlined in 
Figure 6-6a. At the end o f the treatment (day 12), the relative tumor volumes were 10.7 ±
3.4 mm3, 8.3 ± 2 mm3, 6.5 ± 1 mm3, 3.6 ± 0.3 mm3, and 2.9 ±0.1 mm3 for vehicle 
controls, Free DOX, NLC-DOX, NLC-DOX-LBL and NLC-DOX-LBL-PEG, 
respectively. The more efficient treatments for inhibition of tumor growth contained 
NLC-DOX-LBL-PEG, which was most apparent by day 12. Plain NLC-DOX were 
somewhat more effective than Free DOX. The NLC-DOXs formulated with LbL clearly 
(P < 0 .05) inhibited the tumor’s growth.
Figure 6-6b shows the tumor weights after excision at day +12. The tumors of 
mice treated with NLC-DOX-LBL and NLC-DOX-LBL-PEG had a consistently lower 
weight. There was no tumor weight difference among vehicle controls, free DOX and 
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Figure 6-6: (a) Evaluation of the relative tumor volume and (b) tumor weight excised at 
day 12. The mice were inoculated with 4T1 cells and treated with Saline (Control), Free 
DOX, NLC-DOX, NLC-DOX-LBL or NLC-DOX-LBL-PEG. N= 5-6. Average ± SD. 
One way ANOVA was used considering day by day. The post test was Newman-Keuls. 
In collaboration with Dr. V. Torchilin at Northeastern University, Boston, MA.
6.3.5 Mice evaluation
Mice were monitored for significant signs of toxicity using observations of 
behavior and body weight changes. Figure 6-7 describes the variation of the mouse’s 
weight from day 0 baseline over the 12-day treatment period. The control group
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maintained a consistent increase in body weight of almost a gram. With the exception of 
the NLC-DOX-LBL-PEG, which had an initial weight loss followed by a late recovery, 
the DOX-treated groups had only small weight fluctuations.
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Figure 6-7: Variations of the mice weight according to the treatment. N = 3 to 6. 
Average ± SD. One way ANOVA with Newman-Keuls post test. In collaboration 
with Dr. V. Torchilin at Northeastern University, Boston, MA.
6.4 Conclusion
Our proposed core shell nanostructured lipid carrier (NLC) loaded with DOX and 
DHA and modified with LBL show the size, zeta potential, and stability characteristics 
needed for a controlled release after parental administration. The NLC-DOX-LBL and 
NLC-DOX-LBL-PEG had a better size distribution of 128±2 nm, with a polydispersity of 
0.098, a more sustained DOX release, improved pharmacokinetics, a higher plasma 
concentration of DOX in LbL and PEG samples approximately 2.5 and 3.0 times 
respectively against NLC-DOX samples. It showed approximately 2.9 and 2.2 lower 
accumulation in the liver for LbL and PEG samples respectively as compared to NLC-
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DOX samples. Simultaneously, it showed approximately 1.5 and 1.75 higher 
accumulation in tumors for LbL and PEG samples, respectively, as compared to NLC- 
DOX samples, and an enhanced effect on tumor growth inhibition. Thus, the attachment 
of LbL to the surface of NLC loaded with DOX represents a potential improvement in 
anticancer therapy. The steps in the process of LbL coating can be reduced by optimizing 
conditions with the exact amount of polyelectrolyte needed per layer so that multiple 
layers can be assembled with fewer steps more rapidly and efficiently.
In conclusion, the concepts of: 1) washless LbL for encapsulation of nanocores, as 
learned in CHAPTER 4, and 2) reduction of the number of PE layers (e.g. 2.5 bilayers on 
nano lipid cores) have been applied to achieve a narrow particle size distribution with 
high colloidal stability of 100-120 nm hydrodynamic size.
CHAPTER 7
CONCLUSION AND FUTURE WORK
7.1 Conclusion
1) An essential step forward has been taken in the application of LbL self-assembly 
for effective 100-170 nm encapsulation of low soluble anticancer drugs with a loading of 
40-60 wt. % in various forms of nano-cores: meso-crystalline drug soft cores, 
nanomiceller carriers, and nanostructured lipid cores incorporating low soluble drugs.
LbL polymer assembly acts as an adjustable interface between the drug loaded matrix 
core and the external environment of the blood. It provides a colloidal stability of nano 
structures in a dispersion. It acted as an effective modality to functionalize the outermost 
surface with long tails of poly ethylene glycol (PEG) for longer circulation, and 
monoclonal antibodies. It thus proves a basis for targeted delivery of low soluble drugs, 
with prolonged circulation in serum and improved biodistribution to the targeted organ. 
All the polymers used are biocompatible substances that are FDA approved which was 
another challenge as compared with earlier developed LbL encapsulation technique based 
on synthetic polyelectrolytes.
2) LbL assembly technique was for the first time used for encapsulation of low 
soluble drug under two-step of pH, from pH 3 to 7.2. It is performed specifically to 
preserve the active form of an anticancer drug, CPT, i.e. lactone form. Employment of 
washless LbL assembly technique and optimization of PE architecture helped to attain a
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high drug loading capacity of 78 w %, retained the active form of CPT by 99 % lactone 
fraction. The PEG tails modified surface further provided the high protein resistance, 
decreased the initial burst of drug release and prolonged the overall release time in the 
serum for more than 4 h. By preserving the active lactone form, it simultaneously 
improved the cytotoxicity against glioblastoma cell lines, CRL2303, three-fold.
3) Concepts learned from CPT LbL formulation have been well applied for 
encapsulating a nano miceller PTX core. The milestones achieved were: reducing the 
number of process steps, attaining high colloidal stability of -100 nm for 30 days, high 
drug loading capacity of 30-40%, an approximate 6.5 times higher cyctotoxicity than free 
drug, an improved injectable for delivery into mice model (tumor injected) with a 
survival rate ca. 85% and finally showing a significantly improved antitumor effect. Mice 
experiments were performed in collaboration with Northeastern University, Department 
of Pharmaceutical Science.
4) Finally, the above concepts were applied to improve the anticancer therapy of 
nanostructured lipid carrier (NLC) loaded with DOX and DHA. This was the first time 
that LbL technique has been merged with lipid carrier-based drug delivery. It was 
experimentally shown that LbL assembly improved the colloidal stability by narrowing 
the particle size distribution of 128±2 nm with a polydispersity of 0.098. The LbL and 
high PEGylated NLC-DOX cores proved to have approximate 1.5 times improved 
capacity to preserve the antitumor effect, compared to NLC-DOX. An improved 
biodistribution by 1.5 and 1.75 times higher accumulation in the tumors was observed for 
LbL and high PEGylated samples, respectively.
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7.2 Future Work
Washless LbL assembly has been well explored for the encapsulation of low 
soluble drug in different forms of nano cores. From these approaches, it has been learned 
that it acts as a good encapsulating agent and a cage like structure for different carriers; 
maintaining the colloidal stability as low as 100 nm for weeks is successful in keeping 
the chemical form of the drug along with its function (in this case the anticancer activity). 
Pharmacokinetic improvement in systemic delivery of the drug as injectable has been 
shown to some extent.
Still more pathological study for the toxicity issues has to be studied, as was 
observed in the case of PTX LbL nanomicelles. This work will help us understand the 
cause for survival rate of ca. 85%. It will guide us in the right direction to improve the 
formulation.
A new approach can be developed to form a dual drug delivery system by 
assembling a nanoencapsulation of a Drug I (e.g. nanomicelle of Lapatinib), <100 nm, on 
top of a larger nanoparticle of Drug II (e.g. LbL formulation of CPT), ~ 160 nm. It will 
be important to develop a way to analyze both drugs separately. Such electrostatic bound 
drug cores will be a novel way to deliver multiple drugs at the same time.
Furthermore, washless LbL technique with fewer PE assembly layers has brought 
a milestone in simplifying the tedious process of LbL assembly technique. It can be used 
for large scale processing of coating microbial agents for application in food industries. 
The administration of low soluble protein or protein derivatives (e.g. whey proteins, 
insoluble amino acids -  leucine, isoleucine) supplements for oral administration are in the 
form of drinkable shakes (suspensions) and dry powder (by spray drying).
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Figure A -l: Release profiles of CPT from (Hep/PLB 16-5)5 nanocapsules in FBS (1) and 
lactone fraction retained in the released medium (2) as a function of time. C(CPT), 
pg/mL: 1- 6.7,2- 4.5,3- 2.27 pg/ml. C- free CPT (control), 6.7 pg/mL.
Table A -l: QCM estimation of BSA loss from the core of CPT formulation.
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Figure A-2: % Cell viability vs CPT concentration in extra PEGylated nanocapsules 
treatments; IC50 is indicated.
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B.l Nanomicellar LbL based Paclitaxel formulation
Table B.l-1: Variation of composition of formulation during optimization of PTX loaded 
nanomicelle LbL. Best formulation is highlighted. # AGCX12 is the optimized 
formulation and is indicated as AGCX.
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Figure B.l-1: UV visible spectra of AGCX-LbL (indicated as AGCX(P/H)2.5_super).
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Figure B.l-2: Cytotoxicity results in 4T1 breast cancer cell lines, 4000 cells/well.
First, TPGS was dissolved in CHCb. It was then dried under N2 gas till all the 
CHCb disappears and a thin film of TPGS is formed. PVP in separate container was 
dissolved in 2.5 mL of PBS, 80 mg/mL, 50 pL (approximately 1.43 mg/mL of total 2.5 
mL sample), followed by sonication for 2 min. This mixture was added to the dried 
TPGS film. It was sonicated for 3 min to make a final concentration of approximately 
1.78 mg/mL. Next, Lapatinib (Ltb) drug in DMSO, 7 mg/mL, 200 pL (DMSO) 
(approximately 0.5 mg/mL of total 2.5 mL sample) was added to the above mixture and 
sonicated for an additional 15 min. This nano-miceller core is mentioned as PGL. After 
that, alternating 2.5 bilayers of PLB16-5 and Dextran Sulfate, DS were assembled, with 
PLB16-5 as the outermost layer; 500 pL of this dispersion was extra PEGylated with 
mPEG-SVA (5 kDa) followed by 1 min of sonication (final mPEG-SVA concentration 
being 20 mg/mL). The samples were washed and the supernatant was recovered since the
B.2 Nanomicellar LbL based Lapatinib formulation
B.2.1 Formulation preparation
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color of the supernatant was yellowish (same as the drug). The % Lapatinib encapsulation 
was measured by using calibration curve in the presence of the same concentration of 
TPGS in Ethanol, 0.0864 mg/mL; extinction coefficient 20.241 cm'’mg'1 mL or 
18732.34M'1cm'1 at 333 nm.
Table B.2-1: Lapatinib formulation core composition.
PVP TPGS Ltb Ratio, mg/mg
Final concentration, 
mg/mL
1.43 1.78 0.5 PVP/Ltb TPGS/Ltb
2.86 3.57
r m  Hydrodynamic diameter —♦—Zeta Potential
Figure B.2-1: Zeta potential and hydrodynamic diameter along the formulation process. 
The Ltb % encapsulation is indicated inside the column bars for washed samples of 
PGL(PLB/DS)2.5 and PGL(PLB/DS)2.5/mPEG.
B.2.2 HPLC results
The calibration curve of Lapatinib was run in the mobile phase of Acetyl nitrile / 
Methanol 50:50 v/v, absorbance observed at 232 nm, with a solvent flow rate of 1
113
mL/min. The Lapatinib solution was dissolved in methanol. In the presence of 
polyelectrolytes and polyethylene glycol (PEG) tails, the retention time of Lapatinib had 
shifted. This complicated the analysis of the Lapatinib concentration after LbL assembly 
and extra PEGylation.
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Figure B.2-3: Chromatograms of: (a) Lapatinib 25 ug/mL, (b) LbL samples (Low 
PEGylated), (c) PEGylated samples (High PEGylated) in mobile phase Acetyl 
Nitrile/Water 40/60.
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